{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:57:08Z","timestamp":1793761028514,"version":"4.6.1"},"reference-count":398,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872489, 82073369"],"award-info":[{"award-number":["81872489, 82073369"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02515-3","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:05:42Z","timestamp":1766124342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy"],"prefix":"10.1186","volume":"25","author":[{"given":"Yanna","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diyuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"issue":"8","key":"2515_CR1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807\u201321.","journal-title":"Cell Mol Immunol"},{"key":"2515_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104588","volume":"206","author":"C-Y Hsu","year":"2025","unstructured":"Hsu C-Y, Pallathadka H, Jasim SA, Rizaev J, Olegovich Bokov D, Hjazi A, et al. Innovations in cancer immunotherapy: a comprehensive overview of recent breakthroughs and future directions. Crit Rev Oncol Hematol. 2025;206:104588.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2515_CR3","doi-asserted-by":"crossref","unstructured":"Padmanee S, Sangeeta G, Deblina R, Bilal A S, Pratishtha S, Ashwat N, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186(8):1652\u20131669.","DOI":"10.1016\/j.cell.2023.03.006"},{"issue":"4","key":"2515_CR4","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","volume":"43","author":"U Uslu","year":"2025","unstructured":"Uslu U, June CH. Beyond the blood: expanding CAR T cell therapy to solid tumors. Nat Biotechnol. 2025;43(4):506\u201315.","journal-title":"Nat Biotechnol"},{"issue":"10416","key":"2515_CR5","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023;402(10416):2034\u201344.","journal-title":"Lancet"},{"issue":"1","key":"2515_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64\u201373.","journal-title":"N Engl J Med"},{"issue":"6","key":"2515_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","volume":"13","author":"HJ Jackson","year":"2016","unstructured":"Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13(6):370\u201383.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"2515_CR8","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO-24-02081","volume":"43","author":"S Ouladan","year":"2025","unstructured":"Ouladan S, Orouji E. Chimeric antigen receptor-T cells in colorectal cancer: pioneering new avenues in solid tumor immunotherapy. J Clin Oncol. 2025;43(8):994\u20131005.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2515_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du B, Qin J, Lin B, Zhang J, Li D, Liu M. CAR-T therapy in solid tumors. Cancer Cell. 2025;43(4):665\u201379.","journal-title":"Cancer Cell"},{"issue":"6","key":"2515_CR10","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2515_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01701-6","volume":"18","author":"H Qin","year":"2025","unstructured":"Qin H, Zhou Z, Shi R, Mai Y, Xu Y, Peng F, et al. Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects. J Hematol Oncol. 2025;18(1):62.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2515_CR12","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","volume":"12","author":"RM Young","year":"2022","unstructured":"Young RM, Engel NW, Uslu U, Wellhausen N, June CH. Next-generation CAR T-cell therapies. Cancer Discov. 2022;12(7):1625\u201333.","journal-title":"Cancer Discov"},{"issue":"3","key":"2515_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2515_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"issue":"7971","key":"2515_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619(7971):707\u201315.","journal-title":"Nature"},{"issue":"12","key":"2515_CR16","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","volume":"22","author":"M Ruella","year":"2023","unstructured":"Ruella M, Korell F, Porazzi P, Maus MV. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nat Rev Drug Discov. 2023;22(12):976\u201395.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2515_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00890-6","volume":"13","author":"Y Tian","year":"2020","unstructured":"Tian Y, Li Y, Shao Y, Zhang Y. Gene modification strategies for next-generation CAR T cells against solid cancers. J Hematol Oncol. 2020;13(1):54.","journal-title":"J Hematol Oncol"},{"key":"2515_CR18","doi-asserted-by":"crossref","unstructured":"O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984.","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"2515_CR19","doi-asserted-by":"crossref","unstructured":"Guangna L, Wei R, Xueqiang Z, Xin L. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol Immunol. 2021;18(5):1085\u2013109518.","DOI":"10.1038\/s41423-021-00655-2"},{"key":"2515_CR20","doi-asserted-by":"crossref","unstructured":"Zaoqu L, Zhaokai Z, Qin D, Hui X, Jinxiang L, Huanyun L, et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics. 2022;12(14):6273\u20136290.","DOI":"10.7150\/thno.76854"},{"key":"2515_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217928","volume":"631","author":"Z Li","year":"2025","unstructured":"Li Z, Yang F, Lu S, Wu X, Li S, Wang M. Neuroimmunology-driven CAR T-cell therapeutics for gliomas: translational challenges and clinical trial paradigm innovation. Cancer Lett. 2025;631:217928.","journal-title":"Cancer Lett"},{"issue":"18","key":"2515_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf0108","volume":"9","author":"JS Frieling","year":"2023","unstructured":"Frieling JS, Tordesillas L, Bustos XE, Ramello MC, Bishop RT, Cianne JE, et al. \u0393\u03b4-enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer. Sci Adv. 2023;9(18):eadf0108.","journal-title":"Sci Adv"},{"issue":"1","key":"2515_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/107327481502200114","volume":"22","author":"JS Frieling","year":"2015","unstructured":"Frieling JS, Basanta D, Lynch CC. Current and emerging therapies for bone metastatic castration-resistant prostate cancer. Cancer Control. 2015;22(1):109\u201320.","journal-title":"Cancer Control"},{"key":"2515_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136357","author":"MW Saif","year":"2025","unstructured":"Saif MW, Chang WH, Myers S, Potts M, Qazi S, Trieu V. TgfB2 expression and methylation predict overall survival in pancreatic ductal adenocarcinoma patients. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26136357.","journal-title":"Int J Mol Sci"},{"key":"2515_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132438","author":"A Argentiero","year":"2024","unstructured":"Argentiero A, Andriano A, Caradonna IC, de Martino G, Desantis V. Decoding the intricate landscape of pancreatic cancer: insights into tumor biology, microenvironment, and therapeutic interventions. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16132438.","journal-title":"Cancers (Basel)"},{"key":"2515_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2025.1568865","volume":"12","author":"MR Brogna","year":"2025","unstructured":"Brogna MR, Varone V, DelSesto M, Ferrara G. The role of CAFs in therapeutic resistance in triple negative breast cancer: an emerging challenge. Front Mol Biosci. 2025;12:1568865.","journal-title":"Front Mol Biosci"},{"key":"2515_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1172681","volume":"14","author":"S Das","year":"2023","unstructured":"Das S, Valton J, Duchateau P, Poirot L. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy. Front Immunol. 2023;14:1172681.","journal-title":"Front Immunol"},{"key":"2515_CR28","doi-asserted-by":"crossref","unstructured":"Jake S OD, Michele W L T, Mark J S. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2018;16(3):151\u2013167.","DOI":"10.1038\/s41571-018-0142-8"},{"key":"2515_CR29","doi-asserted-by":"crossref","unstructured":"Matthew M G, Matthew D V. Cancer Immunoediting in the Era of Immuno-oncology. Clin Cancer Res. 2022;28(18)3917\u20133928.","DOI":"10.1158\/1078-0432.CCR-21-1804"},{"key":"2515_CR30","doi-asserted-by":"crossref","unstructured":"Gavin P D, Lloyd J O, Robert D S. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137\u201348.","DOI":"10.1016\/j.immuni.2004.07.017"},{"key":"2515_CR31","doi-asserted-by":"crossref","unstructured":"Martin B, Erik L. Somatic mutation distribution across tumour cohorts provides a signal for positive selection in cancer. Nat Commun. 2022;13(1):7023.","DOI":"10.1038\/s41467-022-34746-z"},{"issue":"5","key":"2515_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","volume":"25","author":"M Roerden","year":"2025","unstructured":"Roerden M, Spranger S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat Rev Immunol. 2025;25(5):353\u201369.","journal-title":"Nat Rev Immunol"},{"key":"2515_CR33","doi-asserted-by":"crossref","unstructured":"Nicholas M, Charles S. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613\u2013628.","DOI":"10.1016\/j.cell.2017.01.018"},{"issue":"2","key":"2515_CR34","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","volume":"27","author":"I Vitale","year":"2021","unstructured":"Vitale I, Shema E, Loi S, Galluzzi L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med. 2021;27(2):212\u201324.","journal-title":"Nat Med"},{"issue":"5","key":"2515_CR35","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.tcb.2019.01.003","volume":"29","author":"I Vitale","year":"2019","unstructured":"Vitale I, Sistigu A, Manic G, Rudqvist NP, Trajanoski Z, Galluzzi L. Mutational and antigenic landscape in tumor progression and cancer immunotherapy. Trends Cell Biol. 2019;29(5):396\u2013416.","journal-title":"Trends Cell Biol"},{"issue":"2","key":"2515_CR36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81\u201394.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2515_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01331-9","volume":"20","author":"W Fang","year":"2021","unstructured":"Fang W, Jin H, Zhou H, Hong S, Ma Y, Zhang Y, et al. Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer. Mol Cancer. 2021;20(1):37.","journal-title":"Mol Cancer"},{"issue":"1","key":"2515_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02334-6","volume":"24","author":"Y Lu","year":"2025","unstructured":"Lu Y, Zhao F. Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy. Mol Cancer. 2025;24(1):126.","journal-title":"Mol Cancer"},{"key":"2515_CR39","doi-asserted-by":"crossref","unstructured":"Andrew J H, Laurence C C, Yvonne Y C. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov. 2021;20(7):531\u2013550.","DOI":"10.1038\/s41573-021-00189-2"},{"key":"2515_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117252","volume":"178","author":"H Lin","year":"2024","unstructured":"Lin H, Yang X, Ye S, Huang L, Mu W. Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies. Biomed Pharmacother. 2024;178:117252.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"2515_CR41","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","volume":"22","author":"AVR Kornepati","year":"2022","unstructured":"Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer. 2022;22(3):174\u201389.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2515_CR42","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1146\/annurev-immunol-101819-024752","volume":"42","author":"HN Bell","year":"2024","unstructured":"Bell HN, Zou W. Beyond the barrier: unraveling the mechanisms of immunotherapy resistance. Annu Rev Immunol. 2024;42(1):521\u201350.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"2515_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0403-5","volume":"10","author":"J Wang","year":"2017","unstructured":"Wang J, Yuan R, Song W, Sun J, Liu D, Li Z. PD-1, PD-L1 (B7\u2013H1) and tumor-site immune modulation therapy: the historical perspective. J Hematol Oncol. 2017;10(1):34.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2515_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0770-2","volume":"7","author":"S Chen","year":"2019","unstructured":"Chen S, Crabill GA, Pritchard TS, McMiller TL, Wei P, Pardoll DM, et al. Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer. 2019;7(1):305.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"2515_CR45","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76(3):359\u201370.","journal-title":"Mol Cell"},{"issue":"1","key":"2515_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01365-z","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wang Y, Yang Y, Weng L, Wu Q, Zhang J, et al. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct Target Ther. 2023;8(1):104.","journal-title":"Signal Transduct Target Ther"},{"key":"2515_CR47","doi-asserted-by":"crossref","unstructured":"Andr\u00e9 V, Jun C. SIRP\u03b1-CD47 Immune checkpoint blockade in anticancer therapy. Trends Immunol. 2018;39(3):173\u2013184.","DOI":"10.1016\/j.it.2017.12.005"},{"key":"2515_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2515_CR49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","volume":"30","author":"I Vitale","year":"2019","unstructured":"Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30(1):36\u201350.","journal-title":"Cell Metab"},{"issue":"10","key":"2515_CR50","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014\u201322.","journal-title":"Nat Immunol"},{"issue":"3","key":"2515_CR51","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"K de Visser","year":"2023","unstructured":"de Visser K, Joyce J. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403.","journal-title":"Cancer Cell"},{"issue":"3","key":"2515_CR52","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"E Arner","year":"2023","unstructured":"Arner E, Rathmell J. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023;41(3):421\u201333.","journal-title":"Cancer Cell"},{"key":"2515_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006401","author":"MM Melssen","year":"2023","unstructured":"Melssen MM, Sheybani ND, Leick KM, Slingluff CL Jr. Barriers to immune cell infiltration in tumors. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-006401.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"2515_CR54","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","volume":"15","author":"KC Valkenburg","year":"2018","unstructured":"Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15(6):366\u201381.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2515_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131.","journal-title":"Mol Cancer"},{"issue":"3","key":"2515_CR56","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo D, Egeblad M, Evans R, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174\u201386.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2515_CR57","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ccr.2009.12.041","volume":"17","author":"N Erez","year":"2010","unstructured":"Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell. 2010;17(2):135\u201347.","journal-title":"Cancer Cell"},{"issue":"3","key":"2515_CR58","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ccell.2023.02.015","volume":"41","author":"G Caligiuri","year":"2023","unstructured":"Caligiuri G, Tuveson DA. Activated fibroblasts in cancer: perspectives and challenges. Cancer Cell. 2023;41(3):434\u201349.","journal-title":"Cancer Cell"},{"issue":"6","key":"2515_CR59","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-22-1031","volume":"29","author":"K Kennel","year":"2023","unstructured":"Kennel K, Bozlar M, De Valk A, Greten F. Cancer-associated fibroblasts in inflammation and antitumor immunity. Clin Cancer Res. 2023;29(6):1009\u201316.","journal-title":"Clin Cancer Res"},{"key":"2515_CR60","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cytogfr.2022.07.006","volume":"67","author":"X Xiang","year":"2022","unstructured":"Xiang X, Niu Y-R, Wang Z-H, Ye L-L, Peng W-B, Zhou Q. Cancer-associated fibroblasts: vital suppressors of the immune response in the tumor microenvironment. Cytokine Growth Factor Rev. 2022;67:35\u201348.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"12","key":"2515_CR61","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1158\/2326-6066.CIR-17-0190","volume":"5","author":"AN Woods","year":"2017","unstructured":"Woods AN, Wilson AL, Srivinisan N, Zeng J, Dutta AB, Peske JD, et al. Differential expression of homing receptor ligands on tumor-associated vasculature that control CD8 effector T-cell entry. Cancer Immunol Res. 2017;5(12):1062\u201373.","journal-title":"Cancer Immunol Res"},{"key":"2515_CR62","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.canlet.2021.01.014","volume":"503","author":"X-Y Tang","year":"2021","unstructured":"Tang X-Y, Ding Y-S, Zhou T, Wang X, Yang Y. Tumor-tagging by oncolytic viruses: a novel strategy for CAR-T therapy against solid tumors. Cancer Lett. 2021;503:69\u201374.","journal-title":"Cancer Lett"},{"issue":"4","key":"2515_CR63","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle E, Massagu\u00e9 J. Transforming growth factor-\u03b2 signaling in immunity and cancer. Immunity. 2019;50(4):924\u201340.","journal-title":"Immunity"},{"issue":"2","key":"2515_CR64","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/ng1001-117","volume":"29","author":"R Derynck","year":"2001","unstructured":"Derynck R, Akhurst R, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001;29(2):117\u201329.","journal-title":"Nat Genet"},{"issue":"8","key":"2515_CR65","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1158\/2159-8290.CD-12-0527","volume":"3","author":"Y Pang","year":"2013","unstructured":"Pang Y, Gara S, Achyut B, Li Z, Yan H, Day C, et al. TGF-\u03b2 signaling in myeloid cells is required for tumor metastasis. Cancer Discov. 2013;3(8):936\u201351.","journal-title":"Cancer Discov"},{"issue":"1","key":"2515_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01349-6","volume":"15","author":"X Shi","year":"2022","unstructured":"Shi X, Yang J, Deng S, Xu H, Wu D, Zeng Q, et al. TGF-\u03b2 signaling in the tumor metabolic microenvironment and targeted therapies. J Hematol Oncol. 2022;15(1):135.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2515_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06654-8","volume":"9","author":"A Chakravarthy","year":"2018","unstructured":"Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD. TGF-\u03b2-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun. 2018;9(1):4692.","journal-title":"Nat Commun"},{"issue":"1","key":"2515_CR68","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1777064","volume":"9","author":"M Alcantara","year":"2020","unstructured":"Alcantara M, Du Rusquec P, Romano E. Current clinical evidence and potential solutions to increase benefit of CAR T-cell therapy for patients with solid tumors. Oncoimmunology. 2020;9(1):1777064.","journal-title":"Oncoimmunology"},{"issue":"5","key":"2515_CR69","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","volume":"18","author":"G Liu","year":"2021","unstructured":"Liu G, Rui W, Zhao X, Lin X. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol Immunol. 2021;18(5):1085\u201395.","journal-title":"Cell Mol Immunol"},{"key":"2515_CR70","unstructured":"Jin J, Jiali C, Meijuan H, Hui L, Jianfeng Z. Fueling chimeric antigen receptor T cells with cytokines. Am J Cancer Res. 22020;10(12):4038\u20134055."},{"issue":"1","key":"2515_CR71","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","volume":"29","author":"K Kohli","year":"2022","unstructured":"Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 2022;29(1):10\u201321.","journal-title":"Cancer Gene Ther"},{"key":"2515_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2023.103020","volume":"84","author":"M Hong","year":"2023","unstructured":"Hong M, Talluri S, Chen YY. Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors. Curr Opin Biotechnol. 2023;84:103020.","journal-title":"Curr Opin Biotechnol"},{"issue":"3","key":"2515_CR73","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","volume":"18","author":"Y Huang","year":"2018","unstructured":"Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol. 2018;18(3):195\u2013203.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2515_CR74","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s43018-021-00241-5","volume":"2","author":"MC Milone","year":"2021","unstructured":"Milone MC, Xu J, Chen S-J, Collins MA, Zhou J, Powell DJ, et al. Engineering-enhanced CAR T cells for improved cancer therapy. Nat Cancer. 2021;2(8):780\u201393.","journal-title":"Nat Cancer"},{"issue":"1","key":"2515_CR75","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21(1):47\u201366.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2515_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01282-8","volume":"15","author":"Y Tie","year":"2022","unstructured":"Tie Y, Tang F, Wei YQ, Wei XW. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol. 2022;15(1):61.","journal-title":"J Hematol Oncol"},{"issue":"14","key":"2515_CR77","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.7150\/thno.76854","volume":"12","author":"Z Liu","year":"2022","unstructured":"Liu Z, Zhou Z, Dang Q, Xu H, Lv J, Li H, et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics. 2022;12(14):6273\u201390.","journal-title":"Theranostics"},{"issue":"2","key":"2515_CR78","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ymthe.2024.12.014","volume":"33","author":"S Zheng","year":"2025","unstructured":"Zheng S, Che X, Zhang K, Bai Y, Deng H. Potentiating CAR-T cell function in the immunosuppressive tumor microenvironment by inverting the TGF-\u03b2 signal. Mol Ther. 2025;33(2):688\u2013702.","journal-title":"Mol Ther"},{"issue":"3","key":"2515_CR79","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41423-023-01123-9","volume":"21","author":"Z Yang","year":"2024","unstructured":"Yang Z, Fu YX. Inactivation of TGF-\u03b2 signaling in CAR-T cells. Cell Mol Immunol. 2024;21(3):309\u201310.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"2515_CR80","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4\u20131BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581\u201390.","journal-title":"Nat Med"},{"issue":"1","key":"2515_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0758-x","volume":"12","author":"J Wei","year":"2019","unstructured":"Wei J, Han X, Bo J, Han W. Target selection for CAR-T therapy. J Hematol Oncol. 2019;12(1):62.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"2515_CR82","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219\u201326.","journal-title":"Cancer Discov"},{"issue":"4","key":"2515_CR83","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s44222-023-00031-x","volume":"1","author":"Y Liu","year":"2023","unstructured":"Liu Y, Sperling AS, Smith EL, Mooney DJ. Optimizing the manufacturing and antitumour response of CAR T therapy. Nat Rev Bioeng. 2023;1(4):271\u201385.","journal-title":"Nat Rev Bioeng"},{"key":"2515_CR84","doi-asserted-by":"crossref","unstructured":"Mohamad H, Jorge M-S, Isabelle R, Michel S. Programming CAR T Cell Tumor Recognition: Tuned antigen sensing and logic gating. Cancer Discov. 2023;13(4):829\u2013843.","DOI":"10.1158\/2159-8290.CD-23-0101"},{"issue":"1","key":"2515_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00910-5","volume":"13","author":"R Huang","year":"2020","unstructured":"Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13(1):86.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2515_CR86","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449\u201359.","journal-title":"N Engl J Med"},{"issue":"1","key":"2515_CR87","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20\u20138.","journal-title":"Nat Med"},{"issue":"6","key":"2515_CR88","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372\u201385.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"2515_CR89","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","volume":"25","author":"AJ Walker","year":"2017","unstructured":"Walker AJ, Majzner RG, Zhang L, Wanhainen K, Long AH, Nguyen SM, et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol Ther. 2017;25(9):2189\u2013201.","journal-title":"Mol Ther"},{"issue":"3","key":"2515_CR90","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ccell.2025.02.008","volume":"43","author":"C Pham-Danis","year":"2025","unstructured":"Pham-Danis C, Novak AJ, Danis E, McClellan SM, Leach L, Yarnell MC, et al. Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia. Cancer Cell. 2025;43(3):482-502.e9.","journal-title":"Cancer Cell"},{"issue":"8","key":"2515_CR91","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, et al. CAR T cells targeting B7\u2013H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25(8):2560\u201374.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2515_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01708-w","volume":"8","author":"Y Zhai","year":"2023","unstructured":"Zhai Y, Du Y, Li G, Yu M, Hu H, Pan C, et al. Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape. Signal Transduct Target Ther. 2023;8(1):457.","journal-title":"Signal Transduct Target Ther"},{"key":"2515_CR93","doi-asserted-by":"crossref","unstructured":"Esther S, Stefanie R, Isabella MN, Paula H, Thomas P, Rolf K, et al. Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality. Oncoimmunology. 2022;11(1):2093426.","DOI":"10.1080\/2162402X.2022.2093426"},{"issue":"1","key":"2515_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01170-7","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin D, et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol. 2021;14(1):161.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"2515_CR95","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood.2019002779","volume":"135","author":"X He","year":"2020","unstructured":"He X, Feng Z, Ma J, Ling S, Cao Y, Gurung B, et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood. 2020;135(10):713\u201323.","journal-title":"Blood"},{"key":"2515_CR96","doi-asserted-by":"crossref","unstructured":"Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019;37(9):1049\u201358.","DOI":"10.1038\/s41587-019-0192-1"},{"issue":"10","key":"2515_CR97","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1093\/neuonc\/noae126","volume":"26","author":"AJ Hou","year":"2024","unstructured":"Hou AJ, Shih RM, Uy BR, Shafer A, Chang ZL, Comin-Anduix B, et al. IL-13R\u03b12\/TGF-\u03b2 bispecific CAR-T cells counter TGF-\u03b2-mediated immune suppression and potentiate anti-tumor responses in glioblastoma. Neuro Oncol. 2024;26(10):1850\u201366.","journal-title":"Neuro Oncol"},{"issue":"7","key":"2515_CR98","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ymthe.2022.05.011","volume":"30","author":"Y Yin","year":"2022","unstructured":"Yin Y, Rodriguez JL, Li N, Thokala R, Nasrallah MP, Hu L, et al. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors. Mol Ther. 2022;30(7):2537\u201353.","journal-title":"Mol Ther"},{"key":"2515_CR99","doi-asserted-by":"crossref","unstructured":"Kanae I, Yuki T, Seitaro T, Shingo O, Yoshitaka A, Masahide O, et al. Dual CAR-T cells targeting CD19 and CD37 are effective in target antigen loss B-cell tumor models. Mol Cancer Ther. 2023;23(3):381\u2013393.","DOI":"10.1158\/1535-7163.MCT-23-0408"},{"issue":"4","key":"2515_CR100","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","volume":"13","author":"M Hamieh","year":"2023","unstructured":"Hamieh M, Mansilla-Soto J, Rivi\u00e8re I, Sadelain M. Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating. Cancer Discov. 2023;13(4):829\u201343.","journal-title":"Cancer Discov"},{"key":"2515_CR101","doi-asserted-by":"crossref","unstructured":"Meenakshi H, Malini M, Zakaria G, Antonella P, Daniel L, Shoba A N, et al. Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape. J Clin Invest. 2016;126(8):3036\u201352.","DOI":"10.1172\/JCI83416"},{"key":"2515_CR102","doi-asserted-by":"crossref","unstructured":"Sara G-M, Fakhri H, Isabel M V-B, Eduardo A-M, Rafael S, Javier C-V. Tandem CAR-T cell therapy: recent advances and current challenges. Front Immunol. 2025;16(0):1546172.","DOI":"10.3389\/fimmu.2025.1546172"},{"key":"2515_CR103","first-page":"127","volume":"11","author":"H Qin","year":"2018","unstructured":"Qin H, Ramakrishna S, Nguyen S, Fountaine TJ, Ponduri A, Stetler-Stevenson M, et al. Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol Ther. 2018;11:127\u201337.","journal-title":"Mol Ther"},{"issue":"1","key":"2515_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00856-8","volume":"13","author":"H Dai","year":"2020","unstructured":"Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):30.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2515_CR105","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"WH Zhao","year":"2018","unstructured":"Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11(1):141.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2515_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01686-z","volume":"8","author":"Y Sun","year":"2023","unstructured":"Sun Y, Yang XN, Yang SS, Lyu YZ, Zhang B, Liu KW, et al. Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity. Signal Transduct Target Ther. 2023;8(1):445.","journal-title":"Signal Transduct Target Ther"},{"issue":"10297","key":"2515_CR107","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"1","key":"2515_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50251-x","volume":"15","author":"M Tian","year":"2024","unstructured":"Tian M, Wei JS, Cheuk AT, Milewski D, Zhang Z, Kim YY, et al. CAR t-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma. Nat Commun. 2024;15(1):6222.","journal-title":"Nat Commun"},{"issue":"10","key":"2515_CR109","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1158\/2326-6066.CIR-21-0062","volume":"9","author":"Y Yang","year":"2021","unstructured":"Yang Y, McCloskey JE, Yang H, Puc J, Alcaina Y, Vedvyas Y, et al. Bispecific CAR T cells against EpCAM and inducible ICAM-1 overcome antigen heterogeneity and generate superior antitumor responses. Cancer Immunol Res. 2021;9(10):1158\u201374.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"2515_CR110","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.apsb.2024.03.027","volume":"14","author":"X Qin","year":"2024","unstructured":"Qin X, Ning W, Liu H, Liu X, Luo W, Xia N. Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy. Acta Pharm Sin B. 2024;14(6):2361\u201377.","journal-title":"Acta Pharm Sin B"},{"issue":"11","key":"2515_CR111","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1007\/s00262-023-03529-w","volume":"72","author":"SS Mun","year":"2023","unstructured":"Mun SS, Meyerberg J, Peraro L, Korontsvit T, Gardner T, Malviya M, et al. Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1. Cancer Immunol Immunother. 2023;72(11):3773\u201386.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"2515_CR112","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41568-022-00451-8","volume":"22","author":"G Xie","year":"2022","unstructured":"Xie G, Gu X. Bidirectional CART.BiTE cells bring new hope. Nat Rev Cancer. 2022;22(4):194.","journal-title":"Nat Rev Cancer"},{"key":"2515_CR113","doi-asserted-by":"crossref","unstructured":"Marc W, Samantha G, Filippo B, Adam K, Yi S, Rebecca C L, et al. Mesothelin CAR T cells secreting anti-FAP\/Anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma. Clin Cancer Res. 2024;30(9):1859\u20131877.","DOI":"10.1158\/1078-0432.CCR-23-3841"},{"issue":"5","key":"2515_CR114","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s13402-024-00971-5","volume":"47","author":"Z Yan","year":"2024","unstructured":"Yan Z, Gu R, Ma H, Chen N, Zhang T, Xu Y, et al. A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells. Cell Oncol (Dordr). 2024;47(5):1879\u201395.","journal-title":"Cell Oncol (Dordr)"},{"key":"2515_CR115","doi-asserted-by":"publisher","unstructured":"Fan Y, Duan Y, Chen J, Wang Y, Shang K, Jiang J, et al. Bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumour responses. Nat Biomed Engine 2025. https:\/\/doi.org\/10.1038\/s41551-025-01450-4.","DOI":"10.1038\/s41551-025-01450-4"},{"issue":"5","key":"2515_CR116","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1111\/bjh.19348","volume":"204","author":"H Brillembourg","year":"2024","unstructured":"Brillembourg H, Mart\u00ednez-Cibri\u00e1n N, Bachiller M, Alserawan L, Ortiz-Maldonado V, Guedan S, et al. The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies. Br J Haematol. 2024;204(5):1649\u201359.","journal-title":"Br J Haematol"},{"issue":"5","key":"2515_CR117","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood.2019003293","volume":"135","author":"J Pan","year":"2020","unstructured":"Pan J, Zuo S, Deng B, Xu X, Li C, Zheng Q, et al. Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL. Blood. 2020;135(5):387\u201391.","journal-title":"Blood"},{"issue":"7750","key":"2515_CR118","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568(7750):112\u20136.","journal-title":"Nature"},{"issue":"9","key":"2515_CR119","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.22.01214","volume":"41","author":"T Wang","year":"2023","unstructured":"Wang T, Tang Y, Cai J, Wan X, Hu S, Lu X, et al. Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial. J Clin Oncol. 2023;41(9):1670\u201383.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2515_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-024-01364-2","volume":"57","author":"J Kim","year":"2025","unstructured":"Kim J, Park S, Kim J, Kim Y, Yoon HM, Rayhan BR, et al. Trogocytosis-mediated immune evasion in the tumor microenvironment. Exp Mol Med. 2025;57(1):1\u201312.","journal-title":"Exp Mol Med"},{"key":"2515_CR121","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010702","author":"A Hinckley-Boned","year":"2025","unstructured":"Hinckley-Boned A, Barbero-Jim\u00e9nez C, Trist\u00e1n-Manzano M, Maldonado-Perez N, Hudecek M, Justicia-Lirio P, et al. Tailoring CAR surface density and dynamics to improve CAR-T cell therapy. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2024-010702.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"2515_CR122","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/s41375-022-01585-2","volume":"36","author":"ML Olson","year":"2022","unstructured":"Olson ML, V Mause ER, Radhakrishnan SV, Brody JD, Rapoport AP, Welm AL, et al. Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion. Leukemia. 2022;36(7):1943\u20136.","journal-title":"Leukemia"},{"issue":"11","key":"2515_CR123","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1158\/0008-5472.CAN-20-2701","volume":"81","author":"E Schoutrop","year":"2021","unstructured":"Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R, et al. Mesothelin-specific CAR T cells target ovarian cancer. Cancer Res. 2021;81(11):3022\u201335.","journal-title":"Cancer Res"},{"key":"2515_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00949-8","author":"W Zhong","year":"2025","unstructured":"Zhong W, Qin Z, Yu Z, Yang J, Yan D, Engel NW, et al. Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors. Nat Cancer. 2025. https:\/\/doi.org\/10.1038\/s43018-025-00949-8.","journal-title":"Nat Cancer"},{"issue":"103","key":"2515_CR125","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ado2054","volume":"10","author":"S Barbera","year":"2025","unstructured":"Barbera S, Schuiling MJA, Sanjaya NA, Pietil\u00e4 I, Sar\u00e9n T, Essand M, et al. Trogocytosis of chimeric antigen receptors between T cells is regulated by their transmembrane domains. Sci Immunol. 2025;10(103):eado2054.","journal-title":"Sci Immunol"},{"key":"2515_CR126","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009013","author":"R Freeman","year":"2024","unstructured":"Freeman R, Shahid S, Khan AG, Mathew SC, Souness S, Burns ER, et al. Developing a membrane-proximal CD33-targeting CAR T cell. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-009013.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2515_CR127","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1380764","volume":"7","author":"SJ Priceman","year":"2018","unstructured":"Priceman SJ, Gerdts EA, Tilakawardane D, Kennewick KT, Murad JP, Park AK, et al. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. Oncoimmunology. 2018;7(2):e1380764.","journal-title":"Oncoimmunology"},{"issue":"5","key":"2515_CR128","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 2020;10(5):702\u201323.","journal-title":"Cancer Discov"},{"issue":"1","key":"2515_CR129","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccell.2021.12.005","volume":"40","author":"S Heitzeneder","year":"2022","unstructured":"Heitzeneder S, Bosse KR, Zhu Z, Zhelev D, Majzner RG, Radosevich MT, et al. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell. 2022;40(1):53-69.e9.","journal-title":"Cancer Cell"},{"issue":"1","key":"2515_CR130","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccell.2021.12.010","volume":"40","author":"A Hotblack","year":"2022","unstructured":"Hotblack A, Straathof K. Fine-tuning CARs for best performance. Cancer Cell. 2022;40(1):11\u20133.","journal-title":"Cancer Cell"},{"issue":"7786","key":"2515_CR131","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, et al. C-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576(7786):293\u2013300.","journal-title":"Nature"},{"issue":"9","key":"2515_CR132","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi K, Du H, Xu Y, Shou P, Zhou X, Fuc\u00e1 G, et al. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat Cancer. 2021;2(9):904\u201318.","journal-title":"Nat Cancer"},{"issue":"623","key":"2515_CR133","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh1962","volume":"13","author":"A Katsarou","year":"2021","unstructured":"Katsarou A, Sj\u00f6strand M, Naik J, Mansilla-Soto J, Kefala D, Kladis G, et al. Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Sci Transl Med. 2021;13(623):eabh1962.","journal-title":"Sci Transl Med"},{"key":"2515_CR134","doi-asserted-by":"crossref","unstructured":"Catherine P-D, Amanda J N, Etienne D, Samantha M M, Lillie L, Michael C Y, et al. Restoration of LAT activity improves CAR T\u00a0cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia. Cancer Cell. 2025;43(3):482\u2013502.e9.","DOI":"10.1016\/j.ccell.2025.02.008"},{"issue":"6382","key":"2515_CR135","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science"},{"issue":"1","key":"2515_CR136","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01198-2","volume":"7","author":"Q Ma","year":"2022","unstructured":"Ma Q, He X, Zhang B, Guo F, Ou X, Yang Q, et al. A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis. Signal Transduct Target Ther. 2022;7(1):380.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"2515_CR137","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.4049\/jimmunol.169.10.5538","volume":"169","author":"T Yamazaki","year":"2002","unstructured":"Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 2002;169(10):5538\u201345.","journal-title":"J Immunol"},{"issue":"7","key":"2515_CR138","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1172\/JCI85796","volume":"126","author":"A Saha","year":"2016","unstructured":"Saha A, O\u2019Connor RS, Thangavelu G, Lovitch SB, Dandamudi DB, Wilson CB, et al. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest. 2016;126(7):2642\u201360.","journal-title":"J Clin Invest"},{"issue":"1","key":"2515_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33793-w","volume":"13","author":"L Qin","year":"2022","unstructured":"Qin L, Cui Y, Yuan T, Chen D, Zhao R, Li S, et al. Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis. Nat Commun. 2022;13(1):6051.","journal-title":"Nat Commun"},{"issue":"8","key":"2515_CR140","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.4049\/jimmunol.1203085","volume":"191","author":"C Ankri","year":"2013","unstructured":"Ankri C, Shamalov K, Horovitz-Fried M, Mauer S, Cohen CJ. Human T cells engineered to express a programmed death 1\/28 costimulatory retargeting molecule display enhanced antitumor activity. J Immunol. 2013;191(8):4121\u20139.","journal-title":"J Immunol"},{"issue":"5","key":"2515_CR141","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00262-006-0272-1","volume":"56","author":"C Blank","year":"2007","unstructured":"Blank C, Mackensen A. Contribution of the PD-L1\/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007;56(5):739\u201345.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2515_CR142","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","volume":"27","author":"H Liu","year":"2021","unstructured":"Liu H, Lei W, Zhang C, Yang C, Wei J, Guo Q, et al. CD19-specific CAR T cells that express a PD-1\/CD28 chimeric switch-receptor are effective in patients with PD-L1\u2013positive B-cell lymphoma. Clin Cancer Res. 2021;27(2):473\u201384.","journal-title":"Clin Cancer Res"},{"issue":"3\u20134","key":"2515_CR143","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.molimm.2012.03.023","volume":"51","author":"ME Prosser","year":"2012","unstructured":"Prosser ME, Brown CE, Shami AF, Forman SJ, Jensen MC. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol Immunol. 2012;51(3\u20134):263\u201372.","journal-title":"Mol Immunol"},{"issue":"6","key":"2515_CR144","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","volume":"76","author":"X Liu","year":"2016","unstructured":"Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 2016;76(6):1578\u201390.","journal-title":"Cancer Res"},{"issue":"7","key":"2515_CR145","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s12275-024-00133-0","volume":"62","author":"HJ Lee","year":"2024","unstructured":"Lee HJ, Hwang SJ, Jeong EH, Chang MH. Genetically engineered CLDN18.2 CAR-T cells expressing synthetic PD1\/CD28 fusion receptors produced using a lentiviral vector. J Microbiol. 2024;62(7):555\u201368.","journal-title":"J Microbiol"},{"issue":"1","key":"2515_CR146","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1901434","volume":"10","author":"C Chen","year":"2021","unstructured":"Chen C, Gu YM, Zhang F, Zhang ZC, Zhang YT, He YD, et al. Construction of PD1\/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer. Oncoimmunology. 2021;10(1):1901434.","journal-title":"Oncoimmunology"},{"issue":"2","key":"2515_CR147","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jcyt.2022.10.006","volume":"25","author":"K Supimon","year":"2023","unstructured":"Supimon K, Sangsuwannukul T, Sujjitjoon J, Chieochansin T, Junking M, Yenchitsomanus PT. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells. Cytotherapy. 2023;25(2):148\u201361.","journal-title":"Cytotherapy"},{"issue":"1","key":"2515_CR148","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2265703","volume":"12","author":"J Zhao","year":"2023","unstructured":"Zhao J, Dong J, Deng C, Zhang Q, Sun S, Li H, et al. Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor. Oncoimmunology. 2023;12(1):2265703.","journal-title":"Oncoimmunology"},{"issue":"1","key":"2515_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0721-y","volume":"7","author":"S Hoogi","year":"2019","unstructured":"Hoogi S, Eisenberg V, Mayer S, Shamul A, Barliya T, Cohen CJ. A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function. J Immunother Cancer. 2019;7(1):243.","journal-title":"J Immunother Cancer"},{"issue":"16","key":"2515_CR150","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1182\/blood.2022016101","volume":"141","author":"MM Dacek","year":"2023","unstructured":"Dacek MM, Kurtz KG, Wallisch P, Pierre SA, Khayat S, Bourne CM, et al. Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRP\u03b1 checkpoint blocker. Blood. 2023;141(16):2003\u201315.","journal-title":"Blood"},{"issue":"4","key":"2515_CR151","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s11684-017-0543-6","volume":"11","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Zhang X, Cheng C, Mu W, Liu X, Li N, et al. CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells. Front Med. 2017;11(4):554\u201362.","journal-title":"Front Med"},{"issue":"1","key":"2515_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, et al. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7(1):737.","journal-title":"Sci Rep"},{"issue":"1","key":"2515_CR153","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01559-z","volume":"21","author":"A Dimitri","year":"2022","unstructured":"Dimitri A, Herbst F, Fraietta J. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022;21(1):78.","journal-title":"Mol Cancer"},{"issue":"8","key":"2515_CR154","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130\u201344.","journal-title":"J Clin Invest"},{"issue":"10","key":"2515_CR155","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","volume":"56","author":"S Agarwal","year":"2023","unstructured":"Agarwal S, Aznar MA, Rech AJ, Good CR, Kuramitsu S, Da T, et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity. 2023;56(10):2388-407.e9.","journal-title":"Immunity"},{"issue":"9","key":"2515_CR156","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","volume":"18","author":"Z Wang","year":"2021","unstructured":"Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu Y, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021;18(9):2188\u201398.","journal-title":"Cell Mol Immunol"},{"issue":"16_suppl","key":"2515_CR157","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.1089","volume":"42","author":"Y Lin","year":"2024","unstructured":"Lin Y, Yin H, Zhou C, Zhou L, Zeng Y, Yao H. Phase I clinical trial of MUC1-targeted CAR-T cells with PD-1-knockout in the treatment of advanced breast cancer. J Clin Oncol. 2024;42(16_suppl):1089.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2515_CR158","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ymthe.2021.10.004","volume":"30","author":"YH Lee","year":"2022","unstructured":"Lee YH, Lee HJ, Kim HC, Lee Y, Nam SK, Hupperetz C, et al. PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. Mol Ther. 2022;30(2):579\u201392.","journal-title":"Mol Ther"},{"issue":"2","key":"2515_CR159","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1273302","volume":"6","author":"N Chen","year":"2017","unstructured":"Chen N, Morello A, Tano Z, Adusumilli PS. CAR T-cell intrinsic PD-1 checkpoint blockade: a two-in-one approach for solid tumor immunotherapy. Oncoimmunology. 2017;6(2):e1273302.","journal-title":"Oncoimmunology"},{"issue":"1_Supplement","key":"2515_CR160","doi-asserted-by":"publisher","first-page":"68.05","DOI":"10.4049\/jimmunol.210.Supp.68.05","volume":"210","author":"A Amador","year":"2023","unstructured":"Amador A, Hou Z, Chintala N, Adusumilli PS. CAR T-cell intrinsic PD1 dominant negative receptor (PD1DNR) functions by both cell-intrinsic and extrinsic mechanisms. J Immunol. 2023;210(1_Supplement):68.05-68.05.","journal-title":"J Immunol"},{"issue":"1","key":"2515_CR161","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00989-w","volume":"13","author":"TC Kuo","year":"2020","unstructured":"Kuo TC, Chen A, Harrabi O, Sockolosky JT, Zhang A, Sangalang E, et al. Targeting the myeloid checkpoint receptor SIRP\u03b1 potentiates innate and adaptive immune responses to promote anti-tumor activity. J Hematol Oncol. 2020;13(1):160.","journal-title":"J Hematol Oncol"},{"key":"2515_CR162","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","volume":"76","author":"K Weiskopf","year":"2017","unstructured":"Weiskopf K. Cancer immunotherapy targeting the CD47\/SIRP\u03b1 axis. Eur J Cancer. 2017;76:100\u20139.","journal-title":"Eur J Cancer"},{"key":"2515_CR163","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005857","author":"AN Beckett","year":"2023","unstructured":"Beckett AN, Chockley P, Pruett-Miller SM, Nguyen P, Vogel P, Sheppard H, et al. CD47 expression is critical for CAR T-cell survival in vivo. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-005857.","journal-title":"J Immunother Cancer"},{"issue":"8016","key":"2515_CR164","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","volume":"630","author":"SA Yamada-Hunter","year":"2024","unstructured":"Yamada-Hunter SA, Theruvath J, McIntosh BJ, Freitas KA, Lin F, Radosevich MT, et al. Engineered CD47 protects T cells for enhanced antitumour immunity. Nature. 2024;630(8016):457\u201365.","journal-title":"Nature"},{"issue":"4","key":"2515_CR165","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015;28(4):415\u201328.","journal-title":"Cancer Cell"},{"key":"2515_CR166","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010028","author":"L Cao","year":"2024","unstructured":"Cao L, Peng H, Chen Y, Xia B, Zeng T, Guo J, et al. Icos-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-010028.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"2515_CR167","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","volume":"35","author":"NF Kuhn","year":"2019","unstructured":"Kuhn NF, Purdon TJ, van Leeuwen DG, Lopez AV, Curran KJ, Daniyan AF, et al. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell. 2019;35(3):473-88.e6.","journal-title":"Cancer Cell"},{"key":"2515_CR168","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1064339","volume":"13","author":"S Ung","year":"2022","unstructured":"Ung S, Choochuen P, Khopanlert W, Maneechai K, Sangkhathat S, Terakura S, et al. Enrichment of T-cell proliferation and memory gene signatures of CD79A\/CD40 costimulatory domain potentiates CD19CAR-T cell functions. Front Immunol. 2022;13:1064339.","journal-title":"Front Immunol"},{"issue":"9","key":"2515_CR169","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1038\/s41375-019-0417-9","volume":"33","author":"MR Collinson-Pautz","year":"2019","unstructured":"Collinson-Pautz MR, Chang WC, Lu A, Khalil M, Crisostomo JW, Lin PY, et al. Constitutively active MyD88\/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies. Leukemia. 2019;33(9):2195\u2013207.","journal-title":"Leukemia"},{"issue":"4","key":"2515_CR170","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227\u201342.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2515_CR171","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/mt.2015.4","volume":"23","author":"KJ Curran","year":"2015","unstructured":"Curran KJ, Seinstra BA, Nikhamin Y, Yeh R, Usachenko Y, van Leeuwen DG, et al. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther. 2015;23(4):769\u201378.","journal-title":"Mol Ther"},{"issue":"5","key":"2515_CR172","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1158\/1078-0432.CCR-12-2064","volume":"19","author":"RH Vonderheide","year":"2013","unstructured":"Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013;19(5):1035\u201343.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2515_CR173","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.103893","volume":"29","author":"C-Z Jian","year":"2024","unstructured":"Jian C-Z, Lin L, Hsu C-L, Chen Y-H, Hsu C, Tan C-T, et al. A potential novel cancer immunotherapy: agonistic anti-CD40 antibodies. Drug Discov Today. 2024;29(3):103893.","journal-title":"Drug Discov Today"},{"issue":"9","key":"2515_CR174","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1016\/j.ymthe.2021.04.038","volume":"29","author":"J Julamanee","year":"2021","unstructured":"Julamanee J, Terakura S, Umemura K, Adachi Y, Miyao K, Okuno S, et al. Composite CD79A\/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival. Mol Ther. 2021;29(9):2677\u201390.","journal-title":"Mol Ther"},{"issue":"4","key":"2515_CR175","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1074\/jbc.M310628200","volume":"279","author":"SA Haxhinasto","year":"2004","unstructured":"Haxhinasto SA, Bishop GA. Synergistic B cell activation by CD40 and the B cell antigen receptor: role of B lymphocyte antigen receptor-mediated kinase activation and tumor necrosis factor receptor-associated factor regulation. J Biol Chem. 2004;279(4):2575\u201382.","journal-title":"J Biol Chem"},{"key":"2515_CR176","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020287","author":"HTT Do","year":"2020","unstructured":"Do HTT, Lee CH, Cho J. Chemokines and their receptors: multifaceted roles in cancer progression and potential value as cancer prognostic markers. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12020287.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2515_CR177","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc1388","volume":"4","author":"F Balkwill","year":"2004","unstructured":"Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540\u201350.","journal-title":"Nat Rev Cancer"},{"issue":"228","key":"2515_CR178","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007240","volume":"6","author":"B Mlecnik","year":"2014","unstructured":"Mlecnik B, Bindea G, Angell HK, Sasso MS, Obenauf AC, Fredriksen T, et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med. 2014;6(228):228ra37.","journal-title":"Sci Transl Med"},{"issue":"1","key":"2515_CR179","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02079-8","volume":"23","author":"X Xia","year":"2024","unstructured":"Xia X, Yang Z, Lu Q, Liu Z, Wang L, Du J, et al. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy. Mol Cancer. 2024;23(1):175.","journal-title":"Mol Cancer"},{"issue":"6","key":"2515_CR180","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2217\/imt-2021-0228","volume":"14","author":"PF Zhang","year":"2022","unstructured":"Zhang PF, Wang C, Zhang L, Li Q. Reversing chemokine\/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells. Immunotherapy. 2022;14(6):459\u201373.","journal-title":"Immunotherapy"},{"issue":"9","key":"2515_CR181","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559\u201372.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2515_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100543","volume":"3","author":"J Foeng","year":"2022","unstructured":"Foeng J, Comerford I, McColl SR. Harnessing the chemokine system to home CAR-T cells into solid tumors. Cell Rep Med. 2022;3(3):100543.","journal-title":"Cell Rep Med"},{"issue":"1","key":"2515_CR183","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01995-y","volume":"22","author":"NMF Abdalsalam","year":"2024","unstructured":"Abdalsalam NMF, Ibrahim A, Saliu MA, Liu T-M, Wan X, Yan D. MDSC: a new potential breakthrough in CAR-T therapy for solid tumors. Cell Commun Signal. 2024;22(1):612.","journal-title":"Cell Commun Signal"},{"issue":"11","key":"2515_CR184","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","volume":"31","author":"R Sun","year":"2023","unstructured":"Sun R, Sun Y, Wu C, Liu Y, Zhou M, Dong Y, et al. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03baB\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer. Mol Ther. 2023;31(11):3193\u2013209.","journal-title":"Mol Ther"},{"issue":"15","key":"2515_CR185","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-2463","volume":"22","author":"C Alfaro","year":"2016","unstructured":"Alfaro C, Teijeira A, O\u00f1ate C, P\u00e9rez G, Sanmamed MF, Andueza MP, et al. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin Cancer Res. 2016;22(15):3924\u201336.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2515_CR186","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1158\/1078-0432.CCR-20-1319","volume":"27","author":"A Teijeira","year":"2021","unstructured":"Teijeira A, Garasa S, Ochoa MC, Villalba M, Olivera I, Cirella A, et al. IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy. Clin Cancer Res. 2021;27(9):2383\u201393.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2515_CR187","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11869-4","volume":"10","author":"L Jin","year":"2019","unstructured":"Jin L, Tao H, Karachi A, Long Y, Hou AY, Na M, et al. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun. 2019;10(1):4016.","journal-title":"Nat Commun"},{"issue":"5","key":"2515_CR188","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03642-4","volume":"73","author":"JW Cao","year":"2024","unstructured":"Cao JW, Lake J, Impastato R, Chow L, Perez L, Chubb L. Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 co-expression on functional activity. Cancer Immunol Immunother. 2024;73(5):77.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2515_CR189","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/eji.201948457","volume":"50","author":"G Liu","year":"2020","unstructured":"Liu G, Rui W, Zheng H, Huang D, Yu F, Zhang Y, et al. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur J Immunol. 2020;50(5):712\u201324.","journal-title":"Eur J Immunol"},{"issue":"4","key":"2515_CR190","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03648-y","volume":"73","author":"Z Dai","year":"2024","unstructured":"Dai Z, Lin X, Wang X, Zou X, Yan Y, Wang R, et al. Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma. Cancer Immunol Immunother. 2024;73(4):61.","journal-title":"Cancer Immunol Immunother"},{"key":"2515_CR191","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050674","author":"LM Whilding","year":"2019","unstructured":"Whilding LM, Halim L, Draper B, Parente-Pereira AC, Zabinski T, Davies DM, et al. CAR T-cells targeting the integrin \u03b1v\u03b26 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11050674.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2515_CR192","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.scib.2020.12.027","volume":"66","author":"L Jin","year":"2021","unstructured":"Jin L, Cao L, Zhu Y, Cao J, Li X, Zhou J, et al. Enhance anti-lung tumor efficacy of chimeric antigen receptor-T cells by ectopic expression of C\u2013C motif chemokine receptor 6. Sci Bull. 2021;66(8):803\u201312.","journal-title":"Sci Bull"},{"issue":"14","key":"2515_CR193","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","volume":"17","author":"EK Moon","year":"2011","unstructured":"Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011;17(14):4719\u201330.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2515_CR194","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","volume":"33","author":"JA Craddock","year":"2010","unstructured":"Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010;33(8):780\u20138.","journal-title":"J Immunother"},{"key":"2515_CR195","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.628906","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang J, Yang X, Yang J, Lu P, Zhao L, et al. Chemokine receptor CCR2b enhanced anti-tumor function of chimeric antigen receptor T cells targeting mesothelin in a non-small-cell lung carcinoma model. Front Immunol. 2021;12:628906.","journal-title":"Front Immunol"},{"key":"2515_CR196","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32020079","author":"I Klabukov","year":"2025","unstructured":"Klabukov I, Kabakov AE, Yakimova A, Baranovskii D, Sosin D, Atiakshin D, et al. Tumor-associated extracellular matrix obstacles for CAR-T cell therapy: approaches to overcoming. Curr Oncol. 2025. https:\/\/doi.org\/10.3390\/curroncol32020079.","journal-title":"Curr Oncol"},{"issue":"12","key":"2515_CR197","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1073\/pnas.91.12.5657","volume":"91","author":"MJ Scanlan","year":"1994","unstructured":"Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA. 1994;91(12):5657\u201361.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2515_CR198","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1111\/cas.16285","volume":"115","author":"S Meng","year":"2024","unstructured":"Meng S, Hara T, Miura Y, Ishii H. Fibroblast activation protein constitutes a novel target of chimeric antigen receptor T-cell therapy in solid tumors. Cancer Sci. 2024;115(11):3532\u201342.","journal-title":"Cancer Sci"},{"issue":"2","key":"2515_CR199","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","volume":"2","author":"LC Wang","year":"2014","unstructured":"Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. 2014;2(2):154\u201366.","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"2515_CR200","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/mt.2013.110","volume":"21","author":"S Kakarla","year":"2013","unstructured":"Kakarla S, Chow KK, Mata M, Shaffer DR, Song XT, Wu MF, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther. 2013;21(8):1611\u201320.","journal-title":"Mol Ther"},{"issue":"1","key":"2515_CR201","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04080-z","volume":"21","author":"Y Liu","year":"2023","unstructured":"Liu Y, Sun Y, Wang P, Li S, Dong Y, Zhou M, et al. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer. J Transl Med. 2023;21(1):255.","journal-title":"J Transl Med"},{"key":"2515_CR202","doi-asserted-by":"publisher","first-page":"v501","DOI":"10.1093\/annonc\/mdz253.052","volume":"30","author":"A Curioni","year":"2019","unstructured":"Curioni A, Britschgi C, Hiltbrunner S, Bankel L, Gulati P, Weder W, et al. 1226P - A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells. Ann Oncol. 2019;30:v501.","journal-title":"Ann Oncol"},{"issue":"6","key":"2515_CR203","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1084\/jem.20130110","volume":"210","author":"E Tran","year":"2013","unstructured":"Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210(6):1125\u201335.","journal-title":"J Exp Med"},{"issue":"1","key":"2515_CR204","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00544-0","volume":"6","author":"J Huang","year":"2021","unstructured":"Huang J, Zhang L, Wan D, Zhou L, Zheng S, Lin S, et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct Target Ther. 2021;6(1):153.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2515_CR205","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01252-0","volume":"15","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Zhang H, Wang J, Liu Y, Luo T, Hua H. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. J Hematol Oncol. 2022;15(1):34.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2515_CR206","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0556-6","volume":"7","author":"DE Kuczek","year":"2019","unstructured":"Kuczek DE, Larsen AMH, Thorseth ML, Carretta M, Kalvisa A, Siersb\u00e6k MS, et al. Collagen density regulates the activity of tumor-infiltrating T cells. J Immunother Cancer. 2019;7(1):68.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2515_CR207","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21(5):524\u20139.","journal-title":"Nat Med"},{"issue":"12","key":"2515_CR208","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/s41423-024-01228-9","volume":"21","author":"R Zheng","year":"2024","unstructured":"Zheng R, Shen K, Liang S, Lyu Y, Zhang S, Dong H, et al. Specific ECM degradation potentiates the antitumor activity of CAR-T cells in solid tumors. Cell Mol Immunol. 2024;21(12):1491\u2013504.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"2515_CR209","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-31-47","volume":"31","author":"A Shimabukuro-Vornhagen","year":"2012","unstructured":"Shimabukuro-Vornhagen A, Draube A, Liebig TM, Rothe A, Kochanek M, von Bergwelt-Baildon MS. The immunosuppressive factors IL-10, TGF-\u03b2, and VEGF do not affect the antigen-presenting function of CD40-activated B cells. J Exp Clin Cancer Res. 2012;31(1):47.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"2515_CR210","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030603","volume":"16","author":"A Losurdo","year":"2024","unstructured":"Losurdo A, Di Muzio A, Cianciotti BC, Dipasquale A, Persico P, Barigazzi C, et al. T cell features in glioblastoma may guide therapeutic strategies to overcome microenvironment immunosuppression. Cancers (Basel). 2024;16(3):603.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2515_CR211","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","volume":"8","author":"DA Thomas","year":"2005","unstructured":"Thomas DA, Massagu\u00e9 J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005;8(5):369\u201380.","journal-title":"Cancer Cell"},{"issue":"1","key":"2515_CR212","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1023\/A:1022951824806","volume":"21","author":"S Wojtowicz-Praga","year":"2003","unstructured":"Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs. 2003;21(1):21\u201332.","journal-title":"Invest New Drugs"},{"issue":"12","key":"2515_CR213","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.2174\/138920111798808392","volume":"12","author":"S Lonning","year":"2011","unstructured":"Lonning S, Mannick J, McPherson JM. Antibody targeting of TGF-\u03b2 in cancer patients. Curr Pharm Biotechnol. 2011;12(12):2176\u201389.","journal-title":"Curr Pharm Biotechnol"},{"key":"2515_CR214","doi-asserted-by":"crossref","unstructured":"Christopher C K, Jihyun L, Aaron Z, Fang C, Jan Joseph M, Simon F L, et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther. 2018;26(7):1855\u20131866.","DOI":"10.1016\/j.ymthe.2018.05.003"},{"issue":"4","key":"2515_CR215","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28(4):724\u201334.","journal-title":"Nat Med"},{"key":"2515_CR216","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133977","author":"N Tang","year":"2020","unstructured":"Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W, et al. TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.133977.","journal-title":"JCI Insight"},{"issue":"3","key":"2515_CR217","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41423-023-01120-y","volume":"21","author":"S Liang","year":"2024","unstructured":"Liang S, Zheng R, Zuo B, Li J, Wang Y, Han Y, et al. SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors. Cell Mol Immunol. 2024;21(3):213\u201326.","journal-title":"Cell Mol Immunol"},{"key":"2515_CR218","first-page":"144","volume":"21","author":"X Chen","year":"2021","unstructured":"Chen X, Yang S, Li S, Qu Y, Wang HY, Liu J, et al. Secretion of bispecific protein of anti-PD-1 fused with TGF-\u03b2 trap enhances antitumor efficacy of CAR-T cell therapy. Mol Ther. 2021;21:144\u201357.","journal-title":"Mol Ther"},{"issue":"8","key":"2515_CR219","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","volume":"18","author":"ZR Huinen","year":"2021","unstructured":"Huinen ZR, Huijbers EJM, van Beijnum JR, Nowak-Sliwinska P, Griffioen AW. Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat Rev Clin Oncol. 2021;18(8):527\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2515_CR220","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u201340.","journal-title":"Nat Rev Clin Oncol"},{"key":"2515_CR221","doi-asserted-by":"publisher","DOI":"10.3390\/cells11121974","author":"DT Nguyen","year":"2022","unstructured":"Nguyen DT, Ogando-Rivas E, Liu R, Wang T, Rubin J, Jin L, et al. CAR T cell locomotion in solid tumor microenvironment. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11121974.","journal-title":"Cells"},{"key":"2515_CR222","doi-asserted-by":"crossref","unstructured":"Zhen-Ling L, Huan-Huan C, Li-Li Z, Li-Ping S, Lei S. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8(1):198.","DOI":"10.1038\/s41392-023-01460-1"},{"key":"2515_CR223","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005583","author":"X Dong","year":"2023","unstructured":"Dong X, Ren J, Amoozgar Z, Lee S, Datta M, Roberge S, et al. Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-005583.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2515_CR224","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05907-z","volume":"23","author":"S Wu","year":"2025","unstructured":"Wu S, Wei Y, Qiu Y, Ai K, Chen M, Wang H. Inhibition of VEGF signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via Wnt\/\u03b2-catenin pathway. J Transl Med. 2025;23(1):494.","journal-title":"J Transl Med"},{"issue":"2","key":"2515_CR225","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/gutjnl-2021-325808","volume":"72","author":"KM Sullivan","year":"2023","unstructured":"Sullivan KM, Jiang X, Guha P, Lausted C, Carter JA, Hsu C, et al. Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases. Gut. 2023;72(2):325\u201337.","journal-title":"Gut"},{"issue":"5","key":"2515_CR226","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41590-025-02137-3","volume":"26","author":"B Mishra","year":"2025","unstructured":"Mishra B, Bachu M, Yuan R, Wingert C, Chaudhary V, Brauner C, et al. IL-10 targets IRF transcription factors to suppress IFN and inflammatory response genes by epigenetic mechanisms. Nat Immunol. 2025;26(5):748\u201359.","journal-title":"Nat Immunol"},{"issue":"11","key":"2515_CR227","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen J, Andreatta M, Feng B, Xie Y-Q, Wenes M, et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotechnol. 2024;42(11):1693\u2013704.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"2515_CR228","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.stem.2024.02.003","volume":"31","author":"Y Huang","year":"2024","unstructured":"Huang Y, Wang H. From suppressor to enhancer: IL-10\u2019s alternative role in CAR-T cell therapies against solid tumors. Cell Stem Cell. 2024;31(3):285\u20137.","journal-title":"Cell Stem Cell"},{"issue":"26","key":"2515_CR229","doi-asserted-by":"publisher","first-page":"7492","DOI":"10.1016\/j.cell.2024.10.006","volume":"187","author":"G Mollaoglu","year":"2024","unstructured":"Mollaoglu G, Tepper A, Falcomat\u00e0 C, Potak HT, Pia L, Amabile A, et al. Ovarian cancer-derived IL-4 promotes immunotherapy resistance. Cell. 2024;187(26):7492-510.e22.","journal-title":"Cell"},{"issue":"1","key":"2515_CR230","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51978-3","volume":"15","author":"CM Stewart","year":"2024","unstructured":"Stewart CM, Siegler EL, Sakemura RL, Cox MJ, Huynh T, Kimball B, et al. IL-4 drives exhaustion of CD8+ CART cells. Nat Commun. 2024;15(1):7921.","journal-title":"Nat Commun"},{"issue":"1","key":"2515_CR231","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","volume":"25","author":"S Mohammed","year":"2017","unstructured":"Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther. 2017;25(1):249\u201358.","journal-title":"Mol Ther"},{"key":"2515_CR232","doi-asserted-by":"crossref","unstructured":"Alba R-G, Rachel C L, Mathilde P, Monika A E, Lauren C S, Roddy S OC, et al. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nat Commun. 2021;12(1):877.","DOI":"10.1038\/s41467-021-20893-2"},{"key":"2515_CR233","doi-asserted-by":"crossref","unstructured":"Nada Mohamady Farouk A, Abdulrahman I, Muhammad Auwal S, Tzu-Ming L, Xiaochun W, Dehong Y. MDSC: a new potential breakthrough in CAR-T therapy for solid tumors. Cell Commun Signal. 2024;22(1).","DOI":"10.1186\/s12964-024-01995-y"},{"key":"2515_CR234","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.05.025","author":"AM Giudice","year":"2025","unstructured":"Giudice AM, Roth SL, Matlaga S, Cresswell-Clay E, Mishra P, Sch\u00fcrch PM, et al. Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells. Mol Ther. 2025. https:\/\/doi.org\/10.1016\/j.ymthe.2025.05.025.","journal-title":"Mol Ther"},{"key":"2515_CR235","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910828","author":"V Pietrobon","year":"2021","unstructured":"Pietrobon V, Todd LA, Goswami A, Stefanson O, Yang Z, Marincola F. Improving CAR T-cell persistence. Int J Mol Sci. 2021 ;22(19):10828. https:\/\/doi.org\/10.3390\/ijms221910828.","journal-title":"Int J Mol Sci"},{"key":"2515_CR236","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104729","volume":"211","author":"K Wang","year":"2025","unstructured":"Wang K, Ou K, Zeng Y, Yue C, Zhuo Y, Wang L, et al. Epigenetic landscapes drive CAR-T cell kinetics and fate decisions: bridging persistence and resistance. Crit Rev Oncol Hematol. 2025;211:104729.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"2515_CR237","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.cell.2024.03.037","volume":"187","author":"H Chi","year":"2024","unstructured":"Chi H, Pepper M, Thomas PG. Principles and therapeutic applications of adaptive immunity. Cell. 2024;187(9):2052\u201378.","journal-title":"Cell"},{"issue":"21","key":"2515_CR238","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz3223","volume":"6","author":"SE Lindner","year":"2020","unstructured":"Lindner SE, Johnson SM, Brown CE, Wang LD. Chimeric antigen receptor signaling: functional consequences and design implications. Sci Adv. 2020;6(21):eaaz3223.","journal-title":"Sci Adv"},{"issue":"3","key":"2515_CR239","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.coi.2010.02.013","volume":"22","author":"JM Curtsinger","year":"2010","unstructured":"Curtsinger JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol. 2010;22(3):333\u201340.","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"2515_CR240","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1049","volume":"8","author":"R Weinkove","year":"2019","unstructured":"Weinkove R, George P, Dasyam N, McLellan AD. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin Transl Immunol. 2019;8(5):e1049.","journal-title":"Clin Transl Immunol"},{"issue":"6","key":"2515_CR241","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1433518","volume":"7","author":"C Quintarelli","year":"2018","unstructured":"Quintarelli C, Orlando D, Boffa I, Guercio M, Polito VA, Petretto A, et al. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology. 2018;7(6):e1433518.","journal-title":"Oncoimmunology"},{"issue":"1","key":"2515_CR242","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltab016","volume":"1","author":"AJ Harrison","year":"2021","unstructured":"Harrison AJ, Du X, von Scheidt B, Kershaw MH, Slaney CY. Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers. Immunotherapy Advances. 2021;1(1):ltab016.","journal-title":"Immunotherapy Advances"},{"issue":"1","key":"2515_CR243","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13880-1","volume":"11","author":"A Sheih","year":"2020","unstructured":"Sheih A, Voillet V, Hanafi LA, DeBerg HA, Yajima M, Hawkins R, et al. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nat Commun. 2020;11(1):219.","journal-title":"Nat Commun"},{"issue":"26","key":"2515_CR244","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1182\/blood.2023020935","volume":"141","author":"MV Maus","year":"2023","unstructured":"Maus MV. Signatures of dysfunctional CAR T cells. Blood. 2023;141(26):3127\u20139.","journal-title":"Blood"},{"issue":"1","key":"2515_CR245","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07136-7","volume":"9","author":"SM Chin","year":"2018","unstructured":"Chin SM, Kimberlin CR, Roe-Zurz Z, Zhang P, Xu A, Liao-Chan S, et al. Structure of the 4\u20131BB\/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab. Nat Commun. 2018;9(1):4679.","journal-title":"Nat Commun"},{"issue":"8","key":"2515_CR246","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a002436","volume":"2","author":"JS Boomer","year":"2010","unstructured":"Boomer JS, Green JM. An enigmatic tail of CD28 signaling. Cold Spring Harb Perspect Biol. 2010;2(8):a002436.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"11","key":"2515_CR247","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","volume":"18","author":"KM Cappell","year":"2021","unstructured":"Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4\u20131BB costimulatory domains. Nat Rev Clin Oncol. 2021;18(11):715\u201327.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2515_CR248","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(2):380\u201390.","journal-title":"Immunity"},{"issue":"1","key":"2515_CR249","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","volume":"21","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, Mukherjee M, Srinivasan M, Krenciute G, Dakhova O, Zheng Y, et al. Tonic 4\u20131BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent. Cell Rep. 2017;21(1):17\u201326.","journal-title":"Cell Rep"},{"key":"2515_CR250","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051050","author":"A Textor","year":"2021","unstructured":"Textor A, Grunewald L, Anders K, Klaus A, Schwiebert S, Winkler A, et al. CD28 co-stimulus achieves superior CAR T cell effector function against solid tumors than 4-1BB co-stimulus. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13051050.","journal-title":"Cancers (Basel)"},{"key":"2515_CR251","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102931","volume":"58","author":"J Jayaraman","year":"2020","unstructured":"Jayaraman J, Mellody MP, Hou AJ, Desai RP, Fung AW, Pham AHT, et al. CAR-T design: elements and their synergistic function. EBioMedicine. 2020;58:102931.","journal-title":"EBioMedicine"},{"issue":"7","key":"2515_CR252","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","volume":"14","author":"SJ van der Stegen","year":"2015","unstructured":"van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14(7):499\u2013509.","journal-title":"Nat Rev Drug Discov"},{"issue":"26","key":"2515_CR253","first-page":"3153","volume":"141","author":"ME Selli","year":"2023","unstructured":"Selli ME, Landmann JH, Terekhova M, Lattin J, Heard A, Hsu YS, et al. Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction. Blood. 2023;141(26):3153\u201365.","journal-title":"Blood"},{"issue":"3","key":"2515_CR254","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.4049\/jimmunol.179.3.1427","volume":"179","author":"T So","year":"2007","unstructured":"So T, Croft M. Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells. J Immunol. 2007;179(3):1427\u201330.","journal-title":"J Immunol"},{"issue":"12","key":"2515_CR255","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1002\/ijc.25960","volume":"129","author":"AA Hombach","year":"2011","unstructured":"Hombach AA, Abken H. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int J Cancer. 2011;129(12):2935\u201344.","journal-title":"Int J Cancer"},{"issue":"4","key":"2515_CR256","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4161\/onci.19855","volume":"1","author":"AA Hombach","year":"2012","unstructured":"Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology. 2012;1(4):458\u201366.","journal-title":"Oncoimmunology"},{"key":"2515_CR257","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011564","author":"S Herbrich","year":"2025","unstructured":"Herbrich S, Chaib M, Sharma P. Icos-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2025-011564.","journal-title":"J Immunother Cancer"},{"key":"2515_CR258","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-33","volume":"6","author":"CJ Shen","year":"2013","unstructured":"Shen CJ, Yang YX, Han EQ, Cao N, Wang YF, Wang Y, et al. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. J Hematol Oncol. 2013;6:33.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2515_CR259","doi-asserted-by":"publisher","first-page":"547","DOI":"10.4161\/onci.19458","volume":"1","author":"DG Song","year":"2012","unstructured":"Song DG, Powell DJ. Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy. Oncoimmunology. 2012;1(4):547\u20139.","journal-title":"Oncoimmunology"},{"issue":"2","key":"2515_CR260","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2024.01.011","volume":"57","author":"CA Jaeger-Ruckstuhl","year":"2024","unstructured":"Jaeger-Ruckstuhl CA, Lo Y, Fulton E, Waltner OG, Shabaneh TB, Simon S, et al. Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks. Immunity. 2024;57(2):287-302.e12.","journal-title":"Immunity"},{"issue":"3","key":"2515_CR261","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1182\/blood-2011-03-344275","volume":"119","author":"DG Song","year":"2012","unstructured":"Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ Jr. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood. 2012;119(3):696\u2013706.","journal-title":"Blood"},{"issue":"5","key":"2515_CR262","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41434-021-00257-7","volume":"30","author":"X Liang","year":"2023","unstructured":"Liang X, Huang Y, Li D, Yang X, Jiang L, Zhou W, et al. Distinct functions of CAR-T cells possessing a dectin-1 intracellular signaling domain. Gene Ther. 2023;30(5):411\u201320.","journal-title":"Gene Ther"},{"issue":"48","key":"2515_CR263","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg9721","volume":"9","author":"D Li","year":"2023","unstructured":"Li D, Guo X, Yang K, Yang Y, Zhou W, Huang Y, et al. EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors. Sci Adv. 2023;9(48):eadg9721.","journal-title":"Sci Adv"},{"issue":"12","key":"2515_CR264","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100457","volume":"2","author":"T Muliaditan","year":"2021","unstructured":"Muliaditan T, Halim L, Whilding LM, Draper B, Achkova DY, Kausar F, et al. Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors. Cell Rep Med. 2021;2(12):100457.","journal-title":"Cell Rep Med"},{"issue":"3","key":"2515_CR265","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200837","volume":"32","author":"W Khopanlert","year":"2024","unstructured":"Khopanlert W, Choochuen P, Maneechai K, Jangphattananont N, Ung S, Okuno S, et al. Co-stimulation of CD28\/CD40 signaling molecule potentiates CAR-T cell efficacy and stemness. Mol Ther Oncolytics. 2024;32(3):200837.","journal-title":"Mol Ther Oncolytics"},{"issue":"12","key":"2515_CR266","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","volume":"26","author":"CA Ramos","year":"2018","unstructured":"Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, et al. In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin\u2019s lymphomas. Mol Ther. 2018;26(12):2727\u201337.","journal-title":"Mol Ther"},{"issue":"4","key":"2515_CR267","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1053\/j.gastro.2009.10.057","volume":"138","author":"B Mlecnik","year":"2010","unstructured":"Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2010;138(4):1429\u201340.","journal-title":"Gastroenterology"},{"issue":"11","key":"2515_CR268","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","volume":"31","author":"L Tang","year":"2023","unstructured":"Tang L, Pan S, Wei X, Xu X, Wei Q. Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development. Mol Ther. 2023;31(11):3146\u201362.","journal-title":"Mol Ther"},{"issue":"10","key":"2515_CR269","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41573-023-00746-x","volume":"22","author":"WJ Leonard","year":"2023","unstructured":"Leonard WJ, Lin JX. Strategies to therapeutically modulate cytokine action. Nat Rev Drug Discov. 2023;22(10):827\u201354.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"2515_CR270","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jcyt.2014.12.002","volume":"17","author":"T Gargett","year":"2015","unstructured":"Gargett T, Brown MP. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2. Cytotherapy. 2015;17(4):487\u201395.","journal-title":"Cytotherapy"},{"issue":"24","key":"2515_CR271","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123(24):3750\u20139.","journal-title":"Blood"},{"issue":"10","key":"2515_CR272","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s13238-019-0643-y","volume":"10","author":"J Zhou","year":"2019","unstructured":"Zhou J, Jin L, Wang F, Zhang Y, Liu B, Zhao T. Chimeric antigen receptor T (CAR-T) cells expanded with IL-7\/IL-15 mediate superior antitumor effects. Protein Cell. 2019;10(10):764\u20139.","journal-title":"Protein Cell"},{"issue":"5","key":"2515_CR273","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo CF, et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol Res. 2019;7(5):759\u201372.","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"2515_CR274","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.it.2015.10.003","volume":"36","author":"N Arenas-Ramirez","year":"2015","unstructured":"Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: biology, design and application. Trends Immunol. 2015;36(12):763\u201377.","journal-title":"Trends Immunol"},{"issue":"10","key":"2515_CR275","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","volume":"18","author":"R Spolski","year":"2018","unstructured":"Spolski R, Li P, Leonard WJ. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat Rev Immunol. 2018;18(10):648\u201359.","journal-title":"Nat Rev Immunol"},{"issue":"6379","key":"2515_CR276","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1126\/science.aar3246","volume":"359","author":"JT Sockolosky","year":"2018","unstructured":"Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science. 2018;359(6379):1037\u201342.","journal-title":"Science"},{"key":"2515_CR277","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02339-4","author":"T Rakhshandehroo","year":"2024","unstructured":"Rakhshandehroo T, Mantri SR, Moravej H, Louis BBV, Salehi Farid A, Munaretto L, et al. A CAR enhancer increases the activity and persistence of CAR T cells. Nat Biotechnol. 2024. https:\/\/doi.org\/10.1038\/s41587-024-02339-4.","journal-title":"Nat Biotechnol"},{"issue":"6625","key":"2515_CR278","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1624","volume":"378","author":"GM Allen","year":"2022","unstructured":"Allen GM, Frankel NW, Reddy NR, Bhargava HK, Yoshida MA, Stark SR, et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science. 2022;378(6625):eaba1624.","journal-title":"Science"},{"issue":"625","key":"2515_CR279","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg6986","volume":"13","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Hresko ME, Picton LK, Su L, Hollander MJ, Nunez-Cruz S, et al. A human orthogonal IL-2 and IL-2R\u03b2 system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. Sci Transl Med. 2021;13(625):eabg6986.","journal-title":"Sci Transl Med"},{"issue":"3","key":"2515_CR280","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 2018;24(3):352\u20139.","journal-title":"Nat Med"},{"issue":"4","key":"2515_CR281","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","volume":"121","author":"N Cieri","year":"2013","unstructured":"Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. 2013;121(4):573\u201384.","journal-title":"Blood"},{"issue":"12","key":"2515_CR282","doi-asserted-by":"publisher","first-page":"7315","DOI":"10.4049\/jimmunol.172.12.7315","volume":"172","author":"R Carrio","year":"2004","unstructured":"Carrio R, Bathe OF, Malek TR. Initial antigen encounter programs CD8+ T cells competent to develop into memory cells that are activated in an antigen-free, IL-7- and IL-15-rich environment. J Immunol. 2004;172(12):7315\u201323.","journal-title":"J Immunol"},{"key":"2515_CR283","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115740","volume":"168","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Farooq MA, Ajmal I, He C, Gao Y, Guo D, et al. Co-expression of IL-4\/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment. Biomed Pharmacother. 2023;168:115740.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2515_CR284","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02154-0","volume":"23","author":"C Zhang","year":"2024","unstructured":"Zhang C, Liu T, Li S, Teng X, Zhu Y, Zhang G, et al. Membrane-bound IL-7 immobilized by the CD8 transmembrane region improves efficacy of CD19 CAR-T cell therapy. Mol Cancer. 2024;23(1):236.","journal-title":"Mol Cancer"},{"issue":"11","key":"2515_CR285","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","volume":"7","author":"T Shum","year":"2017","unstructured":"Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, et al. Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. Cancer Discov. 2017;7(11):1238\u201347.","journal-title":"Cancer Discov"},{"issue":"6","key":"2515_CR286","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03685-7","volume":"73","author":"N Sakunrangsit","year":"2024","unstructured":"Sakunrangsit N, Khuisangeam N, Inthanachai T, Yodsurang V, Taechawattananant P, Suppipat K, et al. Incorporating IL7 receptor alpha signaling in the endodomain of B7H3-targeting chimeric antigen receptor T cells mediates antitumor activity in glioblastoma. Cancer Immunol Immunother. 2024;73(6):98.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"2515_CR287","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36(4):346\u201351.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2515_CR288","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01128-9","volume":"14","author":"N Pang","year":"2021","unstructured":"Pang N, Shi J, Qin L, Chen A, Tang Y, Yang H, et al. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol. 2021;14(1):118.","journal-title":"J Hematol Oncol"},{"key":"2515_CR289","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.609421","volume":"12","author":"D Duan","year":"2021","unstructured":"Duan D, Wang K, Wei C, Feng D, Liu Y, He Q, et al. The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory\/recurrent multiple myeloma. Front Immunol. 2021;12:609421.","journal-title":"Front Immunol"},{"issue":"9","key":"2515_CR290","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1007\/s00262-021-02853-3","volume":"70","author":"S Goto","year":"2021","unstructured":"Goto S, Sakoda Y, Adachi K, Sekido Y, Yano S, Eto M, et al. Enhanced anti-tumor efficacy of IL-7\/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models. Cancer Immunol Immunother. 2021;70(9):2503\u201315.","journal-title":"Cancer Immunol Immunother"},{"issue":"24","key":"2515_CR291","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1158\/0008-5472.CAN-15-1498","volume":"75","author":"K Pilipow","year":"2015","unstructured":"Pilipow K, Roberto A, Roederer M, Waldmann TA, Mavilio D, Lugli E. IL15 and T-cell stemness in T-cell-based cancer immunotherapy. Cancer Res. 2015;75(24):5187\u201393.","journal-title":"Cancer Res"},{"key":"2515_CR292","doi-asserted-by":"crossref","unstructured":"Battram AM, Bachiller M, Lopez V, Fern\u00e1ndez de Larrea C, Urbano-Ispizua A, Mart\u00edn-Antonio B. IL-15 enhances the persistence and function of BCMA-Targeting CAR-T cells compared to IL-2 or IL-15\/IL-7 by limiting CAR-T cell dysfunction and differentiation. Cancers (Basel). 2021;13(14):3534.","DOI":"10.3390\/cancers13143534"},{"key":"2515_CR293","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192203","author":"E Lanitis","year":"2021","unstructured":"Lanitis E, Rota G, Kosti P, Ronet C, Spill A, Seijo B, et al. Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. J Exp Med. 2021. https:\/\/doi.org\/10.1084\/jem.20192203.","journal-title":"J Exp Med"},{"issue":"8047","key":"2515_CR294","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025;637(8047):940\u20136.","journal-title":"Nature"},{"issue":"9","key":"2515_CR295","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1158\/1078-0432.CCR-18-1811","volume":"25","author":"Y Chen","year":"2019","unstructured":"Chen Y, Sun C, Landoni E, Metelitsa L, Dotti G, Savoldo B. Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15. Clin Cancer Res. 2019;25(9):2915\u201324.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2515_CR296","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2358590","volume":"13","author":"S Nie","year":"2024","unstructured":"Nie S, Song Y, Hu K, Zu W, Zhang F, Chen L, et al. CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival. Oncoimmunology. 2024;13(1):2358590.","journal-title":"Oncoimmunology"},{"issue":"3","key":"2515_CR297","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","volume":"8","author":"SA Batra","year":"2020","unstructured":"Batra SA, Rathi P, Guo L, Courtney AN, Fleurence J, Balzeau J, et al. Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma. Cancer Immunol Res. 2020;8(3):309\u201320.","journal-title":"Cancer Immunol Res"},{"key":"2515_CR298","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010545","author":"C Kessel","year":"2025","unstructured":"Kessel C, Rossig C, Abken H. Weal and woe of interleukin-18 in the T cell therapy of cancer. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2024-010545.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2515_CR299","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41584-023-01053-w","volume":"20","author":"E Landy","year":"2024","unstructured":"Landy E, Carol H, Ring A, Canna S. Biological and clinical roles of IL-18 in inflammatory diseases. Nat Rev Rheumatol. 2024;20(1):33\u201347.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"2515_CR300","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","volume":"23","author":"MP Avanzi","year":"2018","unstructured":"Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung K, et al. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep. 2018;23(7):2130\u201341.","journal-title":"Cell Rep"},{"issue":"2","key":"2515_CR301","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1182\/blood.2023022293","volume":"144","author":"BD Ng","year":"2024","unstructured":"Ng BD, Rajagopalan A, Kousa AI, Fischman JS, Chen S, Massa A, et al. IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model. Blood. 2024;144(2):171\u201386.","journal-title":"Blood"},{"issue":"16","key":"2515_CR302","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1158\/1078-0432.CCR-23-3157","volume":"30","author":"L Fischer-Riepe","year":"2024","unstructured":"Fischer-Riepe L, Kailayangiri S, Zimmermann K, Pfeifer R, Aigner M, Altvater B, et al. Preclinical development of CAR T cells with antigen-inducible IL18 enforcement to treat GD2-positive solid cancers. Clin Cancer Res. 2024;30(16):3564\u201377.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2515_CR303","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu B, Ren J, Luo Y, Keith B, Young RM, Scholler J, et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 2017;20(13):3025\u201333.","journal-title":"Cell Rep"},{"key":"2515_CR304","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166028","author":"JE Jaspers","year":"2023","unstructured":"Jaspers JE, Khan JF, Godfrey WD, Lopez AV, Ciampricotti M, Rudin CM, et al. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. J Clin Invest. 2023;133(9):e166028. https:\/\/doi.org\/10.1172\/JCI166028.","journal-title":"J Clin Invest"},{"issue":"7","key":"2515_CR305","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1158\/2159-8290.CD-20-0896","volume":"11","author":"S Lange","year":"2021","unstructured":"Lange S, Sand LGL, Bell M, Patil SL, Langfitt D, Gottschalk S. A chimeric GM-CSF\/IL18 receptor to sustain CAR T-cell function. Cancer Discov. 2021;11(7):1661\u201371.","journal-title":"Cancer Discov"},{"key":"2515_CR306","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150807","author":"S Arcangeli","year":"2022","unstructured":"Arcangeli S, Bove C, Mezzanotte C, Camisa B, Falcone L, Manfredi F, et al. CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/JCI150807.","journal-title":"J Clin Invest"},{"issue":"6","key":"2515_CR307","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101053","volume":"4","author":"IY Jung","year":"2023","unstructured":"Jung IY, Noguera-Ortega E, Bartoszek R, Collins SM, Williams E, Davis M, et al. Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors. Cell Rep Med. 2023;4(6):101053.","journal-title":"Cell Rep Med"},{"issue":"3","key":"2515_CR308","doi-asserted-by":"publisher","DOI":"10.3390\/cancers8030036","volume":"8","author":"V Golubovskaya","year":"2016","unstructured":"Golubovskaya V, Wu L. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers (Basel). 2016;8(3):36.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2515_CR309","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01504-7","volume":"16","author":"Y Bulliard","year":"2023","unstructured":"Bulliard Y, Andersson BS, Baysal MA, Damiano J, Tsimberidou AM. Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy. J Hematol Oncol. 2023;16(1):108.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2515_CR310","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1158\/2159-8290.CD-20-1677","volume":"11","author":"GM Chen","year":"2021","unstructured":"Chen GM, Chen C, Das RK, Gao P, Chen CH, Bandyopadhyay S, et al. Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy. Cancer Discov. 2021;11(9):2186\u201399.","journal-title":"Cancer Discov"},{"issue":"23","key":"2515_CR311","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj2820","volume":"8","author":"Z Bai","year":"2022","unstructured":"Bai Z, Woodhouse S, Zhao Z, Arya R, Govek K, Kim D, et al. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sci Adv. 2022;8(23):eabj2820.","journal-title":"Sci Adv"},{"issue":"5","key":"2515_CR312","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563\u201371.","journal-title":"Nat Med"},{"issue":"8","key":"2515_CR313","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.7150\/thno.107908","volume":"15","author":"D Qin","year":"2025","unstructured":"Qin D, Lei Y, Shu P, Zhang Y, Loh YH, Wang Y, et al. Supercharging CAR-T cells through transcriptional and epigenetic armoring. Theranostics. 2025;15(8):3345\u201367.","journal-title":"Theranostics"},{"issue":"9","key":"2515_CR314","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1016\/j.ymthe.2021.08.003","volume":"29","author":"B Akbari","year":"2021","unstructured":"Akbari B, Ghahri-Saremi N, Soltantoyeh T, Hadjati J, Ghassemi S, Mirzaei HR. Epigenetic strategies to boost CAR T cell therapy. Mol Ther. 2021;29(9):2640\u201359.","journal-title":"Mol Ther"},{"issue":"7990","key":"2515_CR315","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-023-06733-x","volume":"624","author":"P Zhou","year":"2023","unstructured":"Zhou P, Shi H, Huang H, Sun X, Yuan S, Chapman NM, et al. Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer. Nature. 2023;624(7990):154\u201363.","journal-title":"Nature"},{"issue":"1","key":"2515_CR316","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41551-019-0512-2","volume":"4","author":"MW LaFleur","year":"2020","unstructured":"LaFleur MW, Miller BC, Sharpe AH. Prevention of CAR-T-cell dysfunction. Nat Biomed Eng. 2020;4(1):16\u20137.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"2515_CR317","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50485-9","volume":"15","author":"S Zuo","year":"2024","unstructured":"Zuo S, Li C, Sun X, Deng B, Zhang Y, Han Y, et al. C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial. Nat Commun. 2024;15(1):6155.","journal-title":"Nat Commun"},{"issue":"6","key":"2515_CR318","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.ymthe.2024.04.004","volume":"32","author":"T Ahn","year":"2024","unstructured":"Ahn T, Bae EA, Seo H. Decoding and overcoming T cell exhaustion: epigenetic and transcriptional dynamics in CAR-T cells against solid tumors. Mol Ther. 2024;32(6):1617\u201327.","journal-title":"Mol Ther"},{"key":"2515_CR319","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aai8593","author":"T Wu","year":"2016","unstructured":"Wu T, Ji Y, Moseman EA, Xu HC, Manglani M, Kirby M, et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci Immunol. 2016. https:\/\/doi.org\/10.1126\/sciimmunol.aai8593.","journal-title":"Sci Immunol"},{"issue":"5","key":"2515_CR320","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41423-020-0436-5","volume":"18","author":"Q Shan","year":"2021","unstructured":"Shan Q, Hu S, Chen X, Danahy DB, Badovinac VP, Zang C, et al. Ectopic Tcf1 expression instills a stem-like program in exhausted CD8(+) T cells to enhance viral and tumor immunity. Cell Mol Immunol. 2021;18(5):1262\u201377.","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"2515_CR321","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41577-021-00563-6","volume":"22","author":"X Zhao","year":"2022","unstructured":"Zhao X, Shan Q, Xue HH. TCF1 in T cell immunity: a broadened frontier. Nat Rev Immunol. 2022;22(3):147\u201357.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2515_CR322","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/blood.2020009309","volume":"138","author":"W Zheng","year":"2021","unstructured":"Zheng W, Wei J, Zebley CC, Jones LL, Dhungana Y, Wang YD, et al. Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL. Blood. 2021;138(2):122\u201335.","journal-title":"Blood"},{"issue":"8010","key":"2515_CR323","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","volume":"629","author":"AE Doan","year":"2024","unstructured":"Doan AE, Mueller KP, Chen AY, Rouin GT, Chen Y, Daniel B, et al. FOXO1 is a master regulator of memory programming in CAR T cells. Nature. 2024;629(8010):211\u20138.","journal-title":"Nature"},{"issue":"8010","key":"2515_CR324","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","volume":"629","author":"JD Chan","year":"2024","unstructured":"Chan JD, Scheffler CM, Munoz I, Sek K, Lee JN, Huang YK, et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature. 2024;629(8010):201\u201310.","journal-title":"Nature"},{"issue":"1","key":"2515_CR325","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41590-023-01685-w","volume":"25","author":"Z Zhu","year":"2024","unstructured":"Zhu Z, Lou G, Teng X-L, Wang H, Luo Y, Shi W, et al. FOXP1 and KLF2 reciprocally regulate checkpoints of stem-like to effector transition in CAR T cells. Nat Immunol. 2024;25(1):117\u201328.","journal-title":"Nat Immunol"},{"issue":"6735","key":"2515_CR326","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn2337","volume":"387","author":"E Fagerberg","year":"2025","unstructured":"Fagerberg E, Attanasio J, Dien C, Singh J, Kessler EA, Abdullah L, et al. KLF2 maintains lineage fidelity and suppresses CD8 T cell exhaustion during acute LCMV infection. Science. 2025;387(6735):eadn2337.","journal-title":"Science"},{"issue":"7749","key":"2515_CR327","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen J, L\u00f3pez-Moyado IF, Seo H, Lio CJ, Hempleman LJ, Sekiya T, et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567(7749):530\u20134.","journal-title":"Nature"},{"issue":"7764","key":"2515_CR328","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, et al. TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature. 2019;571(7764):211\u20138.","journal-title":"Nature"},{"issue":"25","key":"2515_CR329","doi-asserted-by":"publisher","first-page":"12410","DOI":"10.1073\/pnas.1905675116","volume":"116","author":"H Seo","year":"2019","unstructured":"Seo H, Chen J, Gonz\u00e1lez-Avalos E, Samaniego-Castruita D, Das A, Wang YH, et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion. Proc Natl Acad Sci U S A. 2019;116(25):12410\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"29","key":"2515_CR330","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adh2605","volume":"9","author":"SM Collins","year":"2023","unstructured":"Collins SM, Alexander KA, Lundh S, Dimitri AJ, Zhang Z, Good CR, et al. TOX2 coordinates with TET2 to positively regulate central memory differentiation in human CAR T cells. Sci Adv. 2023;9(29):eadh2605.","journal-title":"Sci Adv"},{"issue":"11","key":"2515_CR331","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ccell.2022.09.013","volume":"40","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhang C, Qiao M, Cheng C, Tang N, Lu S, et al. Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells. Cancer Cell. 2022;40(11):1407-22.e7.","journal-title":"Cancer Cell"},{"issue":"670","key":"2515_CR332","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn7336","volume":"14","author":"IY Jung","year":"2022","unstructured":"Jung IY, Narayan V, McDonald S, Rech AJ, Bartoszek R, Hong G, et al. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Sci Transl Med. 2022;14(670):eabn7336.","journal-title":"Sci Transl Med"},{"issue":"14","key":"2515_CR333","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1182\/blood.2021012714","volume":"139","author":"T Yoshikawa","year":"2022","unstructured":"Yoshikawa T, Wu Z, Inoue S, Kasuya H, Matsushita H, Takahashi Y, et al. Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy. Blood. 2022;139(14):2156\u201372.","journal-title":"Blood"},{"key":"2515_CR334","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.canlet.2021.10.016","volume":"524","author":"Y Zou","year":"2022","unstructured":"Zou Y, Liu B, Li L, Yin Q, Tang J, Jing Z, et al. IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors. Cancer Lett. 2022;524:121\u201330.","journal-title":"Cancer Lett"},{"issue":"7","key":"2515_CR335","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1158\/2159-8290.CD-22-1175","volume":"13","author":"IY Jung","year":"2023","unstructured":"Jung IY, Bartoszek RL, Rech AJ, Collins SM, Ooi SK, Williams EF, et al. Type I interferon signaling via the EGR2 transcriptional regulator potentiates CAR T cell-intrinsic dysfunction. Cancer Discov. 2023;13(7):1636\u201355.","journal-title":"Cancer Discov"},{"key":"2515_CR336","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.193048","author":"R Chen","year":"2025","unstructured":"Chen R, Chen L, Tang Y, Shen X, Wang Y, Tang P, et al. Enhancing the potency of CAR-T cells against solid tumors through transcription factor engineering. JCI Insight. 2025. https:\/\/doi.org\/10.1172\/jci.insight.193048.","journal-title":"JCI Insight"},{"issue":"1","key":"2515_CR337","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20696-x","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Tong C, Dai H, Wu Z, Han X, Guo Y, et al. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat Commun. 2021;12(1):409.","journal-title":"Nat Commun"},{"issue":"6316","key":"2515_CR338","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1126\/science.aae0491","volume":"354","author":"DR Sen","year":"2016","unstructured":"Sen DR, Kaminski J, Barnitz RA, Kurachi M, Gerdemann U, Yates KB, et al. The epigenetic landscape of T cell exhaustion. Science. 2016;354(6316):1165\u20139.","journal-title":"Science"},{"issue":"6","key":"2515_CR339","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.ymthe.2024.05.007","volume":"32","author":"A Ali","year":"2024","unstructured":"Ali A, Zhang Y, DiPersio J. The invisible hand: how epigenetics shapes CAR T cell destiny. Mol Ther. 2024;32(6):1614\u20136.","journal-title":"Mol Ther"},{"issue":"1","key":"2515_CR340","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/2159-8290.CD-22-1319","volume":"14","author":"N Jain","year":"2024","unstructured":"Jain N, Zhao Z, Koche RP, Antelope C, Gozlan Y, Montalbano A, et al. Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T-cell function. Cancer Discov. 2024;14(1):142\u201357.","journal-title":"Cancer Discov"},{"issue":"1","key":"2515_CR341","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/2159-8290.CD-22-1350","volume":"14","author":"S L\u00f3pez-Cobo","year":"2024","unstructured":"L\u00f3pez-Cobo S, Fuentealba JR, Gueguen P, Bont\u00e9 PE, Tsalkitzi K, Chac\u00f3n I, et al. SUV39H1 ablation enhances long-term CAR T function in solid tumors. Cancer Discov. 2024;14(1):120\u201341.","journal-title":"Cancer Discov"},{"issue":"7951","key":"2515_CR342","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41586-022-05692-z","volume":"615","author":"N Jain","year":"2023","unstructured":"Jain N, Zhao Z, Feucht J, Koche R, Iyer A, Dobrin A, et al. TET2 guards against unchecked BATF3-induced CAR T cell expansion. Nature. 2023;615(7951):315\u201322.","journal-title":"Nature"},{"issue":"6","key":"2515_CR343","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.it.2023.03.008","volume":"44","author":"CC Zebley","year":"2023","unstructured":"Zebley CC, Youngblood B. T cell TET2 disruption cuts the breaks on antitumor CAR T cell therapy. Trends Immunol. 2023;44(6):397\u20138.","journal-title":"Trends Immunol"},{"issue":"3","key":"2515_CR344","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ccell.2025.01.013","volume":"43","author":"P Porazzi","year":"2025","unstructured":"Porazzi P, Nason S, Yang Z, Carturan A, Ghilardi G, Guruprasad P, et al. EZH1\/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer Cell. 2025;43(3):537-51.e7.","journal-title":"Cancer Cell"},{"issue":"1","key":"2515_CR345","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","volume":"43","author":"Y Isshiki","year":"2025","unstructured":"Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, et al. Ezh2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. Cancer Cell. 2025;43(1):49-68.e9.","journal-title":"Cancer Cell"},{"key":"2515_CR346","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1389971","volume":"15","author":"BP Satapathy","year":"2024","unstructured":"Satapathy BP, Sheoran P, Yadav R, Chettri D, Sonowal D, Dash CP, et al. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review. Front Immunol. 2024;15:1389971.","journal-title":"Front Immunol"},{"key":"2515_CR347","doi-asserted-by":"crossref","unstructured":"Kyohei M, Hina B, Prasad S A, Zhaohua H. Combinational CAR T-cell therapy for solid tumors: Requisites, rationales, and trials. Pharmacol Ther. 2024;266(0):108763.","DOI":"10.1016\/j.pharmthera.2024.108763"},{"key":"2515_CR348","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020340","author":"DH Yoon","year":"2018","unstructured":"Yoon DH, Osborn MJ, Tolar J, Kim CJ. Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-in CAR-T. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19020340.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2515_CR349","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Rivi\u00e8re I, Solomon SB, Rusch VW, O\u2019Cearbhaill RE, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 2021;11(11):2748\u201363.","journal-title":"Cancer Discov"},{"key":"2515_CR350","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003837","author":"H Ba","year":"2023","unstructured":"Ba H, Dai Z, Zhang Z, Zhang P, Yin B, Wang J, et al. Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2021-003837.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"2515_CR351","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26286","volume":"2","author":"LB John","year":"2013","unstructured":"John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology. 2013;2(10):e26286.","journal-title":"Oncoimmunology"},{"issue":"20","key":"2515_CR352","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","volume":"19","author":"LB John","year":"2013","unstructured":"John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19(20):5636\u201346.","journal-title":"Clin Cancer Res"},{"key":"2515_CR353","first-page":"41","volume":"4","author":"I Serganova","year":"2017","unstructured":"Serganova I, Moroz E, Cohen I, Moroz M, Mane M, Zurita J, et al. Enhancement of PSMA-directed CAR adoptive immunotherapy by PD-1\/PD-L1 blockade. Mol Ther. 2017;4:41\u201354.","journal-title":"Mol Ther"},{"issue":"9","key":"2515_CR354","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","volume":"25","author":"A Heczey","year":"2017","unstructured":"Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, et al. CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol Ther. 2017;25(9):2214\u201324.","journal-title":"Mol Ther"},{"issue":"173","key":"2515_CR355","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005148","volume":"5","author":"SL Liauw","year":"2013","unstructured":"Liauw SL, Connell PP, Weichselbaum RR. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med. 2013;5(173):173sr2.","journal-title":"Sci Transl Med"},{"issue":"7","key":"2515_CR356","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2021.0168","volume":"7","author":"F Hauth","year":"2021","unstructured":"Hauth F, Ho AY, Ferrone S, Duda DG. Radiotherapy to enhance chimeric antigen receptor T-cell therapeutic efficacy in solid tumors: a narrative review. JAMA Oncol. 2021;7(7):1051\u20139.","journal-title":"JAMA Oncol"},{"issue":"10","key":"2515_CR357","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1158\/2326-6066.CIR-22-0840","volume":"11","author":"HT Quach","year":"2023","unstructured":"Quach HT, Skovgard MS, Villena-Vargas J, Bellis RY, Chintala NK, Amador-Molina A, et al. Tumor-targeted nonablative radiation promotes solid tumor CAR T-cell therapy efficacy. Cancer Immunol Res. 2023;11(10):1314\u201331.","journal-title":"Cancer Immunol Res"},{"issue":"31","key":"2515_CR358","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2403002121","volume":"121","author":"U Amit","year":"2024","unstructured":"Amit U, Uslu U, Verginadis II, Kim MM, Motlagh SAO, Diffenderfer ES, et al. Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer. Proc Natl Acad Sci USA. 2024;121(31):e2403002121.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2515_CR359","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1757360","volume":"9","author":"S Murty","year":"2020","unstructured":"Murty S, Haile ST, Beinat C, Aalipour A, Alam IS, Murty T, et al. Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model. Oncoimmunology. 2020;9(1):1757360.","journal-title":"Oncoimmunology"},{"issue":"4","key":"2515_CR360","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-17-1788","volume":"78","author":"T Weiss","year":"2018","unstructured":"Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P. NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Res. 2018;78(4):1031\u201343.","journal-title":"Cancer Res"},{"issue":"11","key":"2515_CR361","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1016\/j.ymthe.2022.07.021","volume":"30","author":"M Zhou","year":"2022","unstructured":"Zhou M, Chen M, Shi B, Di S, Sun R, Jiang H. Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-\u03baB\/Icam1 signaling. Mol Ther. 2022;30(11):3379\u201393.","journal-title":"Mol Ther"},{"issue":"3","key":"2515_CR362","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/1535-7163.MCT-20-0446","volume":"20","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, He L, Sadagopan A, Ma T, Dotti G, Wang Y, et al. Targeting radiation-resistant prostate cancer stem cells by B7\u2013H3 CAR T cells. Mol Cancer Ther. 2021;20(3):577\u201388.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"2515_CR363","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1182\/blood.2023022682","volume":"144","author":"BJ Brinkmann","year":"2024","unstructured":"Brinkmann BJ, Floerchinger A, Schniederjohann C, Roider T, Coelho M, Mack N, et al. CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models. Blood. 2024;144(7):784\u20139.","journal-title":"Blood"},{"issue":"16_suppl","key":"2515_CR364","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e20049","volume":"41","author":"U Patel","year":"2023","unstructured":"Patel U, Oluwole OO, Kassim A, Jayani R, Belliveau P, Savani B, et al. Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies. J Clin Oncol. 2023;41(16_suppl):e20049-e.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2515_CR365","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nrd.2016.178","volume":"15","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2016;15(9):660.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"2515_CR366","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00262-017-2025-8","volume":"66","author":"O Hamid","year":"2017","unstructured":"Hamid O, Hoffner B, Gasal E, Hong J, Carvajal RD. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. Cancer Immunol Immunother. 2017;66(10):1249\u201364.","journal-title":"Cancer Immunol Immunother"},{"key":"2515_CR367","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193405","author":"S Glau\u00df","year":"2024","unstructured":"Glau\u00df S, Neumeyer V, Hanesch L, Marek J, Hartmann N, Wiedemann GM, et al. A novel chimeric oncolytic virus mediates a multifaceted cellular immune response in a syngeneic B16 melanoma model. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16193405.","journal-title":"Cancers (Basel)"},{"key":"2515_CR368","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10060171","author":"T Nguyen","year":"2018","unstructured":"Nguyen T, Avci NG, Shin DH, Martinez-Velez N, Jiang H. Tune up in situ autovaccination against solid tumors with oncolytic viruses. Cancers (Basel). 2018. https:\/\/doi.org\/10.3390\/cancers10060171.","journal-title":"Cancers (Basel)"},{"key":"2515_CR369","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1455163","volume":"15","author":"E Ponterio","year":"2024","unstructured":"Ponterio E, Haas TL, De Maria R. Oncolytic virus and CAR-T cell therapy in solid tumors. Front Immunol. 2024;15:1455163.","journal-title":"Front Immunol"},{"issue":"1","key":"2515_CR370","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02503-8","volume":"7","author":"CY Chen","year":"2017","unstructured":"Chen CY, Wang PY, Hutzen B, Sprague L, Swain HM, Love JK, et al. Cooperation of oncolytic herpes virotherapy and PD-1 blockade in murine rhabdomyosarcoma models. Sci Rep. 2017;7(1):2396.","journal-title":"Sci Rep"},{"issue":"8","key":"2515_CR371","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007209","volume":"14","author":"V Leoni","year":"2018","unstructured":"Leoni V, Vannini A, Gatta V, Rambaldi J, Sanapo M, Barboni C, et al. A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors. PLoS Pathog. 2018;14(8):e1007209.","journal-title":"PLoS Pathog"},{"issue":"8","key":"2515_CR372","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","volume":"42","author":"U Uslu","year":"2024","unstructured":"Uslu U, Castelli S, June CH. CAR T cell combination therapies to treat cancer. Cancer Cell. 2024;42(8):1319\u201325.","journal-title":"Cancer Cell"},{"issue":"8","key":"2515_CR373","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","volume":"18","author":"PK Bommareddy","year":"2018","unstructured":"Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018;18(8):498\u2013513.","journal-title":"Nat Rev Immunol"},{"key":"2515_CR374","doi-asserted-by":"crossref","unstructured":"Guoqing W, Zongliang Z, Kunhong Z, Zeng W, Nian Y, Xin T, et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Mol Ther. 2022;31(1):134\u2013153.","DOI":"10.1016\/j.ymthe.2022.08.021"},{"issue":"3\u20134","key":"2515_CR375","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1089\/hum.2020.278","volume":"32","author":"K McGrath","year":"2021","unstructured":"McGrath K, Dotti G. Combining oncolytic viruses with chimeric antigen receptor T cell therapy. Hum Gene Ther. 2021;32(3\u20134):150\u20137.","journal-title":"Hum Gene Ther"},{"issue":"7","key":"2515_CR376","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-04039-7","volume":"74","author":"MA Aboalela","year":"2025","unstructured":"Aboalela MA, Abdelmoneim M, Matsumura S, Eissa IR, Bustos-Villalobos I, Sibal PA, et al. Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression. Cancer Immunol Immunother. 2025;74(7):202.","journal-title":"Cancer Immunol Immunother"},{"issue":"640","key":"2515_CR377","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn2231","volume":"14","author":"L Evgin","year":"2022","unstructured":"Evgin L, Kottke T, Tonne J, Thompson J, Huff AL, van Vloten J, et al. Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci Transl Med. 2022;14(640):eabn2231.","journal-title":"Sci Transl Med"},{"issue":"8","key":"2515_CR378","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1158\/0008-5472.CAN-16-1577","volume":"77","author":"K Tanoue","year":"2017","unstructured":"Tanoue K, Rosewell Shaw A, Watanabe N, Porter C, Rana B, Gottschalk S, et al. Armed oncolytic adenovirus-expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors. Cancer Res. 2017;77(8):2040\u201351.","journal-title":"Cancer Res"},{"issue":"18","key":"2515_CR379","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","volume":"74","author":"N Nishio","year":"2014","unstructured":"Nishio N, Diaconu I, Liu H, Cerullo V, Caruana I, Hoyos V, et al. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res. 2014;74(18):5195\u2013205.","journal-title":"Cancer Res"},{"issue":"11\u201312","key":"2515_CR380","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1089\/hum.2024.254","volume":"36","author":"L Fang","year":"2025","unstructured":"Fang L, Wang X, Zhang Y, Zhang C, Liu X, Li W, et al. Oncolytic adenovirus armoring with CXCL9 and IL15 shows potent antitumor activity and boosts CAR-T therapy for prostate cancer. Hum Gene Ther. 2025;36(11\u201312):884\u2013901.","journal-title":"Hum Gene Ther"},{"key":"2515_CR381","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104041","volume":"348","author":"Y Li","year":"2020","unstructured":"Li Y, Xiao F, Zhang A, Zhang D, Nie W, Xu T, et al. Oncolytic adenovirus targeting TGF-\u03b2 enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer. Cell Immunol. 2020;348:104041.","journal-title":"Cell Immunol"},{"issue":"5","key":"2515_CR382","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-18-1932","volume":"25","author":"HJ Chon","year":"2019","unstructured":"Chon HJ, Lee WS, Yang H, Kong SJ, Lee NK, Moon ES, et al. Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune-checkpoint blockade. Clin Cancer Res. 2019;25(5):1612\u201323.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2515_CR383","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.ymthe.2020.02.016","volume":"28","author":"CE Porter","year":"2020","unstructured":"Porter CE, Rosewell Shaw A, Jung Y, Yip T, Castro PD, Sandulache VC, et al. Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors. Mol Ther. 2020;28(5):1251\u201362.","journal-title":"Mol Ther"},{"issue":"15","key":"2515_CR384","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma L, Hostetler A, Morgan DM, Maiorino L, Sulkaj I, Whittaker CA, et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186(15):3148-65.e20.","journal-title":"Cell"},{"issue":"5","key":"2515_CR385","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/leu.2017.39","volume":"31","author":"C Rossig","year":"2017","unstructured":"Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S, et al. Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. Leukemia. 2017;31(5):1087\u201395.","journal-title":"Leukemia"},{"issue":"11","key":"2515_CR386","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen A, Haanen J, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29(11):2844\u201353.","journal-title":"Nat Med"},{"key":"2515_CR387","doi-asserted-by":"crossref","unstructured":"Yan-Ruide L, Zibai L, Xinyuan S, Ying F, Lili Y. Boosting CAR-T cell therapy through vaccine synergy. Trends Pharmacol Sci. 2025;46(2):180\u2013199.","DOI":"10.1016\/j.tips.2024.12.004"},{"issue":"6476","key":"2515_CR388","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1126\/science.aay5967","volume":"367","author":"K Reinhard","year":"2020","unstructured":"Reinhard K, Rengstl B, Oehm P, Michel K, Billmeier A, Hayduk N, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science. 2020;367(6476):446\u201353.","journal-title":"Science"},{"key":"2515_CR389","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200844","author":"N Xu","year":"2021","unstructured":"Xu N, Palmer DC, Robeson AC, Shou P, Bommiasamy H, Laurie SJ, et al. STING agonist promotes CAR T cell trafficking and persistence in breast cancer. J Exp Med. 2021. https:\/\/doi.org\/10.1084\/jem.20200844.","journal-title":"J Exp Med"},{"issue":"1","key":"2515_CR390","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55751-4","volume":"16","author":"T Zhu","year":"2025","unstructured":"Zhu T, Xiao Y, Chen Z, Ding H, Chen S, Jiang G, et al. Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung. Nat Commun. 2025;16(1):262.","journal-title":"Nat Commun"},{"issue":"1","key":"2515_CR391","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47692-9","volume":"15","author":"U Uslu","year":"2024","unstructured":"Uslu U, Sun L, Castelli S, Finck AV, Assenmacher C-A, Young RM, et al. The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion. Nat Commun. 2024;15(1):3933.","journal-title":"Nat Commun"},{"key":"2515_CR392","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003351","author":"E Conde","year":"2021","unstructured":"Conde E, Vercher E, Soria-Castellano M, Suarez-Olmos J, Manche\u00f1o U, Elizalde E, et al. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-003351.","journal-title":"J Immunother Cancer"},{"key":"2515_CR393","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-1230","author":"L Marcos-Kovandzic","year":"2025","unstructured":"Marcos-Kovandzic L, Avagliano M, Ben Khelil M, Srikanthan J, Abdallah R, Petrocelli V, et al. Gut microbiota modulation through Akkermansia spp. supplementation increases CAR-T cell potency. Cancer Discov. 2025. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-1230.","journal-title":"Cancer Discov"},{"issue":"82","key":"2515_CR394","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq3016","volume":"8","author":"JJ Peng","year":"2023","unstructured":"Peng JJ, Wang L, Li Z, Ku CL, Ho PC. Metabolic challenges and interventions in CAR T cell therapy. Sci Immunol. 2023;8(82):eabq3016.","journal-title":"Sci Immunol"},{"issue":"6","key":"2515_CR395","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cmet.2025.04.008","volume":"37","author":"C Niu","year":"2025","unstructured":"Niu C, Wei H, Pan X, Wang Y, Song H, Li C, et al. Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming. Cell Metab. 2025;37(6):1426-41.e7.","journal-title":"Cell Metab"},{"issue":"1","key":"2515_CR396","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52666-y","volume":"15","author":"JA Guerrero","year":"2024","unstructured":"Guerrero JA, Klysz DD, Chen Y, Malipatlolla M, Lone J, Fowler C, et al. GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency. Nat Commun. 2024;15(1):8658.","journal-title":"Nat Commun"},{"issue":"7","key":"2515_CR397","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501\u201321.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2515_CR398","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20(1):49\u201362.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02515-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02515-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02515-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T15:04:59Z","timestamp":1769785499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-025-02515-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":398,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2515"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02515-3","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}